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ABSTRACT 
 
Acetyl-CoA carboxylase is an essential enzyme, as it catalyzes the first committed and 
regulated step in fatty-acid biosynthesis in all organisms excepting few Archaea and Eubacteria. 
Acetyl-CoA carboxylase from gram-negative and gram-positive bacteria is a multifunctional 
enzyme composed of three separate proteins. The carboxyltransferase subunit catalyzes the 
transfer of a carboxyl group from carboxybiotin to acetyl-CoA, forming malonyl-CoA. The 
crystal structure of the Escherichia coli (E. coli) carboxyltransferase component of acetyl-CoA 
carboxylase revealed a unique Zn-domain, presumed to mediate nucleic acid binding, that is 
absent in the eukaryotic enzyme. Notably, the Zn-domain, adjacent to the active site of 
carboxyltransferase, makes for a unique target in the development of novel antibiotics capable of 
highly specific binding. Utilizing an Electrophoretic Mobility Shift Assay as part of this study, 
we investigated the nonspecific nucleic-acid binding and substrate (malonyl-CoA and biocytin) 
inhibition of DNA:carboxyltransferase complex formation. Inhibition of carboxyltransferase 
activity by single-stranded DNA, double-stranded DNA, RNA, and heparin was measured in the 
reverse direction with a spectrophotometric assay in which the production of acetyl-CoA was 
coupled with the combined citrate synthase-malate dehydrogenase reaction requiring NAD+ 
reduction (Blanchard and Waldrop, 1998). NADH formation was followed 
spectrophotometrically at 340 nm. We then determined and characterized the mechanism of 
inhibition by tetracycline (and derivatives) on carboxyltransferase from E. coli and 
Staphylococcus aureus. The tetracyclines are broad-spectrum antibiotics that inhibit translation 
by binding to the 30S ribosomal subunit and preventing the binding of the acylated-tRNA to the 
A-site. Tetracycline exhibited competitive inhibition with respect to both malonyl-CoA and 
  
 
vi 
biocytin. Multiple inhibition analyses with a bisubstrate analog showed that tetracycline and the 
substrates can bind to the enzyme simultaneously. Surprisingly, tetracycline did not interfere 
with the DNA-binding properties of carboxyltransferase. This introduction begins with a 
historical perspective of carboxylation reactions. Next biotin and the structure, function and 
practical applications of acetyl-CoA carboxylase are described. Subsequently a review of 
moonlighting enzymes, or those capable of catalyzing reactions in basic metabolism while acting 
as regulators of gene expression, is provided, as are the functions and structures of several types 
of zinc finger. 
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CHAPTER 1 
INTRODUCTION 
SECTION 1 
Overview of Fatty-Acid Biosynthesis 
Most organisms utilize fatty acids in the construction of cell membranes, and 
higher organisms also use them for energy storage, and, the biosynthesis occurs via one 
of two potential routes. Large, multifunctional enzyme complexes, called Type I fatty-
acid synthase or FAS-I (Wakil, 1962), are responsible for synthesizing fatty acids in 
animal cells, in the cytosol of plants and in yeasts (Chang and Hammes, 1989; Singh et 
al., 1985). However, in prokaryotes and plant chloroplasts, separated enzymes 
collectively referred to as FAS-II (Cronan and Waldrop, 2002) catalyze the same 
reactions. Mycobacterium tuberculosis utilizes both pathways, FAS-I and FAS-II (Bhatt 
et al., 2007; Kurth et al., 2009). Excepting the thermoacidophilic archaeon 
Metallosphaera sedula and autotrophic Archaea Sulfolobus metallicus and Acidianus 
infernus, Archaea do not appear to synthesize fatty acids, as most organisms in that 
domain have membranes made of prenylated ether lipids (Boucher et al., 2004; Hayes 
2000) and altogether lack small biotin-carrying proteins (Menendez et al., 1999) 
necessary for biosynthesis of fatty acids. Parasitic bacteria of the genus Mycoplasma do 
not possess a fatty-acid biosynthetic pathway and do not synthesize fatty acids de novo. 
Instead, their source of fatty acids is derived exclusively from their immediate 
environment and must be imported (Romono et al., 1976; McAllister et al., 2006).  
An essential substrate in both FAS-I and -II pathways is malonyl-CoA.  The 
enzyme that synthesizes malonyl-CoA, acetyl-CoA carboxylase, is the focus of this 
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study. The chemistry surrounding the acetyl-CoA carboxylase catalyzed reaction centers 
on the cofactor biotin; thus, this molecule is described before the enzyme is discussed. 
The Biotin Molecule  
Biotin (also called vitamin H or B7), an essential vitamin, acts as a cofactor for a 
group of enzymes catalyzing the transfer of carboxyl groups. Biotin-dependent enzymes 
participate in metabolic reactions, including sodium transport, gluconeogenesis, urea 
degradation, amino-acid catabolism, and fatty-acid synthesis and degradation (Samols et 
al., 1988).  
The History of Biotin  
The biotin molecule was discovered in the 1920s when M.A. Boas found that rats 
fed a diet rich in raw egg whites developed skin rashes and lost their fur, prior to 
becoming paralyzed (Boas 1927; Leitner 1948). It is now known that egg whites contain 
avidin, a protein that irreversibly binds biotin with a Kd of 10-15 mol/L (Bonjour, 1977; 
Green 1975; Roth, 1985). In 1936, biotin was isolated from egg yolks and shown to be a 
growth factor for yeast (Kögl and Tönnis, 1936). However, not until 1949 did its function 
in carbon dioxide metabolism begin to be understood. That year, Lardy and co-workers 
observed that Lactobacillus arabinosum incorporated 14CO2 into aspartate only when 
biotin was present in the growth media (Lardy et al., 1949).  
The function of biotin was further supported after observing biotin-deficient rats 
fix lower levels of 14CO2 into cellular metabolites (i.e., aspartate and citrate) (MacLeod 
and Lardy, 1949). Subsequently, in 1950, researchers observed the biotin-dependent 
incorporation of 13CO2 into oxaloacetate in cell-free extracts of Micrococcus 
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lysodeikticus (Wessman and Werkman, 1950). An association between biotin and an 
enzyme was first discovered when purified avian liver acetyl-CoA carboxylase was found 
to contain biotin (Wakil et al., 1958), suggesting an enzyme cofactor role for biotin. 
Biotin in Nutrition  
Biotin is synthesized by plants, most bacteria and some fungi. The prevalence of 
biotin in virtually every food, in conjunction with its synthesis and secretion via normal 
gastrointestinal flora, makes biotin deficiency extremely rare. Therefore, few diseases 
occur as a result of biotin deficiency; however, protracted parenteral nutrition therapy or 
malnutrition can lead to severe biotin deficiency. Furthermore, an autosomal recessive 
disorder traced to mutations in the genes coding for biotinidase and biotin ligase, two 
enzymes involved in biotin metabolism (Nyhan, 1988), can lead to profound biotin 
deficiency. Sustained biotin deficiency can lead to glucose intolerance (Bender, 1999) 
and is considered teratogenic in mammals (Mock et al., 2002). 
Structure and Chemistry of Biotin  
Biotin carries labile carboxyl groups at the 1′ nitrogen (Figure 1-1). Although Du 
Vigneaud in 1940 worked out the coenzyme chemical formula -- C10H16N2O3S -- and 
suspected a complicated two-ring structure, the complete structure of biotin was not 
determined until 1942 (Melville et al., 1942) and later reproduced through its chemical 
synthesis (Harris et al., 1943). The biotin molecule contains three functional domains: a 
ureido ring attached to a tetrahydrothiophene ring (fused cis to one another) and a valeric 
acid side chain (also in cis, with respect to the ureido ring) (Melville et al., 1942). Biotin 
is covalently attached to biotin-dependent enzymes via an amide linkage between the 
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valeric side chain and the ε-amino group of a specific, highly conserved lysine residue. 
Although biotin contains three chiral carbon atoms, only the d-(+)-biotin isomer is 
biologically active. 
 
 
 
 
 
 
Figure 1-1. Biotin Molecule 
The carboxyl-group-carrying capacity of biotin initially was confirmed when a 
methyl ester derivative of carboxybiotin, isolated from the reaction catalyzed by β- 
methylcrotonyl-CoA carboxylase, was observed to be carboxylated at the 1′ nitrogen 
(Lynen et al., 1961). Subsequently, Lane’s group demonstrated that chemically 
synthesized biotin carboxylated at the 1′ nitrogen position could be used as a substrate for 
acetyl-CoA carboxylase (Guchhait et al., 1974a). 
The cofactor biotin is deprotonated at the 1′ nitrogen and undergoes 
tautomerization into an enol-like form and acts as a nucleophile (Bruice and Hegarty, 
1970). Through high-resolution X-ray crystallographic studies on biotin and biotin 
derivatives, researchers determined that enolization is important for carboxyl-transfer 
reactions (Stallings and DeTitta, 1985). Specifically, a longer carbonyl bond on the 
ureido ring and shorter C2′-N1′ and C2′-N3′ bonds suggests a polarized ureido ring that 
can interact with ions and polar compounds. 
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Biotin-Dependent Enzymes  
All biotin-dependent enzymes follow ping-pong kinetics (Wood and Barden, 
1977; Easterbrook et al., 1978), having two discrete steps, or half-reactions. Each step is 
catalyzed at a separate active site, and biotin transfers the carboxyl group between active 
sites of the enzyme. The half-reactions catalyzed by biotin-dependent enzymes are as 
follows: First, the carboxyl group is transferred from the donor to biotin, forming the 
carboxybiotin intermediate, and, consequently, the carboxyl group from carboxybiotin is 
passed to the carboxyl acceptor. The enzymes are further categorized according to 
whether they catalyze the fixation of CO2 (Class I, Figure 1-2), the decarboxylation with 
release of CO2 as part of bicarbonate (Class II), or the transfer of a carboxyl group from 
one molecule to another (Class III) (Moss and Lane, 1971). 
Carboxylases, or Class I biotin-dependent enzymes, represent the largest class of 
biotin-dependent enzymes and are the only biotin-dependent enzymes in eukaryotes. 
Biotin-dependent carboxylases use bicarbonate as the carbon dioxide source, and fixation 
of carbon requires hydrolysis of one molecule of ATP. Six examples characterize the 
class: pyruvate carboxylase in gluconeogenesis, β-methylcrotonyl-CoA carboxylase in 
amino-acid catabolism, acetyl-CoA carboxylase in fatty-acid synthesis, propionyl-CoA 
carboxylase in fatty-acid oxidation, geranyl-CoA carboxylase in isoprenoid catabolism, 
and urea carboxylase in urea catabolism (Wood and Barden, 1977). 
Decarboxylases, or Class II biotin-dependent enzymes, are limited to the 
membranes of anaerobic prokaryotes. There, they couple the free energy produced from 
decarboxylation with the transport of sodium ions into the periplasm. Concomitantly, the 
electrochemical gradient is used to synthesize ATP (Jitrapakdee and Wallace, 2003), and 
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bicarbonate is released. These enzymes are named according to the molecule that donates 
the carboxyl group, i.e.: oxaloacetate decarboxylase, methylmalonyl-CoA decarboxylase, 
and glutaconyl-CoA decarboxylase. 
Transcarboxylase, or Class III biotin-dependent enzyme, represent the smallest 
group, as the only known enzyme of this class is transcarboxylase. Biotin-dependent 
transcarboxylase is found in the prokaryote Propionibacterium shermanii, in which it 
catalyzes a carboxyl transfer from methylmalonyl-CoA to pyruvate in propionic acid 
synthesis (Gerwin et al., 1969). 
 
 
 
 
Figure 1-2. Net Reactions Catalyzed by Biotin-Dependent Enzymes 
 
Acetyl-CoA Carboxylase, a Biotin-Dependent Carboxylase 
Acetyl-CoA carboxylase catalyzes the first and committed step of the FAS-I and 
FAS-II pathways, which makes it essential for de novo synthesis of long-chain fatty 
acids, and is present in all plants, animals and nearly all bacteria. In a two-step reaction, 
shown in Figure 1-3, the enzyme produces malonyl-CoA from acetyl-CoA in the 
presence of bicarbonate and ATP (Polakis et al., 1974). 
 
 
 
Figure 1-3. Acetyl-CoA Carboxylase-Catalyzed Reaction. 
                Mg2+            
               (I)   HCO3-   +   ATP-Mg2+   +   RH         ADP- Mg2+   +   Pi   +   RCO2-   +   H+   (carboxylation) 
 
(II)   RCO2-   +   H2O   +   2 Na+intracellular      RH   +   HCO3-   +   Na+extracellular   (decarboxylation) 
 
    (III)   RCO2-   +   R’H      RH   +   R’CO2-   (carboxyl transfer) 
  
            Mg2+            
(1)   Enzyme-biotin   +   MgATP   +   HCO3-         Enzyme-biotin-CO2-   +   MgADP   +   Pi 
 
    (2)   Enzyme-biotin-CO2-   +   Acetyl-CoA      Malonyl-CoA   +   Enzyme-biotin 
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The activation of bicarbonate by ATP produces a reactive acyl phosphate 
intermediate called carboxyphosphate. In the presence of biotin, carboxyphosphate 
decomposes and carboxybiotin is formed; this first half-reaction is catalyzed by the biotin 
carboxylase component. The second half-reaction whereby the carboxyl group is 
transferred from carboxybiotin to acetyl-CoA is catalyzed by the carboxyltransferase 
component. The third component of the enzyme, biotin carboxyl carrier protein, contains 
conserved lysine residue to which biotin is covalently attached. In eukaryotes the enzyme 
exists as a single, multifunctional polypeptide chain (Lane et al., 1974). However, 
studying eukaryotic acetyl-CoA carboxylase and establishing the catalytic mechanism 
has proved difficult, as this form of the enzyme does not bind free biotin and purification 
of the multi-enzymatic complex is arduous.  
Though some bacteria, e.g., M. tuberculosis (Norman et al., 1994) and 
Myxococcus xanthus (Kimura et al., 2000), have the biotin carboxyl carrier protein and 
biotin carboxylase components on one polypeptide chain, prokaryotic acetyl-CoA 
carboxylase exists as separable subunits (Guchhait et al., 1974b). In contrast with the 
eukaryotic form of the enzyme, not only do the catalytic subunits of prokaryotic acetyl-
CoA carboxylase remain active in the absence of the other enzymatic components, the 
two catalytic subunits are able to recognize free biotin as a substrate. All subunits of 
bacterial acetyl-CoA carboxylase can be easily studied, because the genes for biotin 
carboxylase (Li and Cronan, 1992a, b) and carboxyltransferase (Blanchard and Waldrop, 
1998) have been cloned, they can be overexpressed and their gene products purified. 
Furthermore, the molecular mass, oligomerization state and Kd (in the biotin-ligating 
reaction) have been dertermined for biotin carboxyl carrier protein (Nenortas and 
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Beckett, 1996), and an assay exists for both biotin carboxylase (Blanchard et al., 1999) 
and carboxyltransferase (Blanchard and Waldrop, 1998). Moreover, crystal structures for 
bacterial biotin carboxylase (Waldrop et al., 1994; Thoden et al., 2000a), 
carboxyltransferase (Bilder et al., 2006) and biotin carboxyl carrier protein (Athappilly et 
al., 1995) have been solved to 2.0 Å resolution or less. These breakthroughs have 
improved our understanding of the relationship between the structure and function of 
acetyl-CoA carboxylase in E. coli and, as a result, have offered insight into the catalytic 
mechanism of other biotin-dependent enzymes. 
Enzyme Biotinylation 
Biotin-dependent enzymes are post-translationally modified via the covalent 
attachment of biotin to the carrier subunit. This is mediated by the enzyme biotin protein 
ligase, also called BirA or biotin holoenzyme synthetase (Chapman-Smith and Cronan, 
1999). The linkage was elucidated after biocytin was isolated from yeast extract as ε-N-
biotinyl-L-lysine; thus, a lysine residue was presumed to be the site of attachment 
(Wright et al., 1952). The site of biotin attachment in the target enzyme occurs in the 
conserved peptide sequence containing Ala-Met-Lys-Met (Samols et al., 1988). Zhao and 
co-workers (Zhao et al., 2009) proposed that, in a two-step mechanism, biotin ligase 
binds biotin and ATP to catalyze synthesis of bio-5′-AMP, while pyrophosphate is 
released. Secondly, biotin is activated via adenylation then transferred to the ε-amino 
group of the lysine residue located 35 residues from the carboxyl terminus of biotin 
carboxyl carrier protein (Choi-Rhee & Cronan, 2003; Lane et al., 1964). 
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Structure of Biotin Carboxyl Carrier Protein 
Biotin carboxyl carrier protein from E. coli, shown in Figure 1-4, is a 16.7 kDa 
protein and in bacteria is generally a separate subunit; yet it is always essential for the in 
vivo reaction catalyzed by acetyl-CoA carboxylase (Choi-Rhee & Cronan, 2003). The 
crystal structure of the C-terminus of biotin carboxyl carrier protein originally was solved 
to 1.8 Å resolution, and the overall fold was described as a capped β-sandwich with 
quasi-dyad symmetry, with each half containing a characteristic hammerhead motif 
(Athappilly et al., 1995). A subsequent multidimensional NMR analysis of the same 
region was used to validate the protein crystal structure (Yao et al., 1997). Aside from the 
biotin-carrying domain, the remainder of the protein consists of a proline-/alanine-rich 
sequence acting as a mobile linker (Cronan, 2002), with no other known function, and an 
N-terminal domain that is involved in dimerization and for interaction with biotin ligase, 
biotin carboxylase and carboxyltransferase (Yao et al., 1997). The stoichiometry of the 
biotin carboxylase:biotin carboxyl carrier protein complex was determined to be a dimer 
of biotin carboxylase plus four biotin carboxyl carrier protein molecules (Choi-Rhee and 
Cronan, 2003). 
Catalytic Mechanism of Biotin Carboxylase  
The reaction catalyzed by biotin carboxylase requires bicarbonate, ATP, biotin, 
and a large free-energy hurdle because a) bicarbonate is a poor electrophile and b) the 1′ 
nitrogen on biotin is weakly nucleophilic. In the course of elucidating the mechanism for 
biotin carboxylase, the first consideration became the fate of ATP.  It was postulated that 
one of two possible scenarios existed -- the first involving ATP interacting directly with 
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biotin, forming an O-phosphobiotin, or, alternatively, ATP interacting with bicarbonate, 
forming carboxyphosphate (Figure 1-5).  Though, Calvin, Pon, and Lynen suggested the 
formation of an O-phosphobiotin intermediate that could interact with bicarbonate to 
form carboxybiotin (Calvin and Pon, 1959; Lynen et al., 1961), the currently accepted 
model involves a carboxyphosphate intermediate. 
 
Figure 1-4. Ribbon Rendering of the Carboxy-Terminal Fragment of the Biotin Carboxyl 
Carrier Protein subunit of acetyl-CoA carboxylase from E. coli, with the lysine residue at 
position 122 shown in color. (Image courtesy of Tyler Broussard) 
 
 
 
 
 
Figure 1-5. Bicarbonate and ATP Form Carboxyphosphate. 
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Carboxyphosphate is said to have a half-life near 70 msec (Sauers et al., 1975); 
thus, trapping it seemed difficult. However, two groups have evidence of the existence of 
this intermediate. While working with carbamyl phosphate synthetase (an enzyme that 
catalyzes the formation of carbamyl phosphate using ATP, bicarbonate, and ammonia), 
Wimmer and co-workers used a method suitable for following a reaction whereby ATP 
reversibly phosphorylates an acceptor molecule. The method was called positional 
isotope exchange (PIX) and allowed for the observation of the bridge-oxygen to 
nonbridge-oxygen interactions during the rotation of the β-phosphate (Wimmer et al., 
1979). As bicarbonate and ATP are used in the reaction, the initial chemistry is thought to 
be nearly identical to the mechanism for biotin carboxylase and by inference is applied to 
biotin carboxylase. In a similar example, also while studying carbamyl phosphate 
synthetase, Powers and Meister trapped carboxyphosphate using a diazomethane 
quencher (Powers and Meister, 1976). This reaction was conducted via the incubation of 
carbamyl phosphate synthetase, H13CO3- and ATP, and the reaction was methylated with 
diazomethane; the resulting 13C product co-chromatographed with trimethyl 
carboxyphosphate. Moreover, while repeating the assay in the presence of labeled ATP, 
molar ratios of the two isotopes were nearly 1-1. Together, these experiments provide 
evidence for the phosphorylation of bicarbonate by ATP. 
In another experiment, researchers—aware that acetyl-CoA carboxylase was 
capable of catalyzing the phosphorylation of ADP if the reaction was run opposite of the 
physiological direction—used an analog of carboxyphosphate, carbamyl phosphate, and 
observed the formation of ATP (Polakis et al., 1972; Polakis et al., 1974; Ashman and 
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Keech, 1975). Furthermore, the enzyme is capable of slow bicarbonate-mediated ATP-
hydrolysis activity in the absence of biotin (Levert et al., 2000).  
The next and possibly strongest piece of evidence supporting the formation of 
carboxyphosphate as an intermediate in the formation of carboxybiotin came from an 
experiment using HC18O 3 while studying propionyl-CoA carboxylase and biotin 
carboxylase. Investigators noted an exchange of 18O from bicarbonate to Pi, suggesting 
direct contact between bicarbonate and the γ-phosphate of ATP (Kaziro et al., 1962; 
Ogita and Knowles, 1988). 
Prior to the subsequent step in the reaction mechanism, i.e. carboxylation of 
biotin, researchers suspected carboxyphosphate either dissociates to carbon dioxide (and 
Pi) before being bound by biotin or that biotin attacks the carboxyl group of 
carboxyphosphate.  In 1998, Gibson and co-workers attempted to determine the presence 
of carbon dioxide as an intermediate in the reaction catalyzed by carbamyl phosphate 
synthetase (Gibson et al., 1998). This enzyme catalyzes the formation of 
carboxyphosphate, and, in the absence of a nitrogen source, carboxyphosphate breaks 
down as bicarbonate and Pi. They measured the rate of ADP formation as an indicator of 
reaction progress while recording pH.  If carboxyphosphate undergoes water-mediated 
hydrolysis, one proton is released for every molecule of carboxyphosphate hydrolyzed.  If 
the pH does not decrease as the reaction proceeds, carboxyphosphate decomposes to 
carbon dioxide and Pi, with subsequent generation of bicarbonate and a proton in the 
presence of water, leaving the pH unchanged. Their results suggested 
carboxyphosphate—and not carbon dioxide—directly carboxylated biotin.  However, 
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more recently, computational chemists Ito and co-workers have suggested the release of 
CO2 from carboxyphosphate (Ito et al., 2008). 
The final aspect of the biotin carboxylase reaction mechanism to address involves 
the activation of biotin.  For the N1′ of biotin to become nucleophilic, it must be 
deprotonated. Tipton and Cleland first proposed the presence of an active-site acid base 
pair in the activation of biotin (Tipton and Cleland, 1988). Specifically, an active-site 
lysine residue was thought to remove the proton from the thiol group of an active-site 
cysteine, while a thiolate anion subsequently removed the N1′ proton of biotin. The 
protonated lysine residue was proposed to stabilize the negative charge at the ureido 
oxygen. However, using site-directed mutagenesis, Levert and co-workers found that a 
substitution of alanine in the place of the active-site cysteine (C230) produced an enzyme 
with near-wild-type activity. In the same work, it was concluded that the lysine positions 
carboxyphosphate for efficient carboxyl transfer to biotin (Levert et al., 2000). Levert 
and co-workers suggested the phosphate oxygens of carboxyphosphate could act to 
deprotonate the N1′ of biotin (Figure 1-6, interaction A). In agreement with this 
hypothesis, Ito and co-workers state that biotin can undergo enolization in the presence of 
carboxyphosphate, as this intermediate serves as a general acid-base catalyst (Ito et al., 
2008), and the carboxyl group donates a proton to the ureido carbonyl (Figure 1-6, 
interaction B).  Moreover, Ito and co-workers suggest that carboxyphosphate collapses 
into CO2 and Pi (Figure 1-6, interaction C) with the resulting “highly labile, bent” CO2 
molecule rapidly condensing (with enolic biotin) into carboxybiotin (Figure 1-6, 
interaction D).  
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Figure 1-6. Activation of Biotinyl-BCCP via Carboxyphosphate. 
 
Structure of Biotin Carboxylase 
The crystal structure of E. coli biotin carboxylase originally solved to 2.4 Å 
resolution (Waldrop et al., 1994) confirmed a homodimer of 50 kilodalton polypeptide 
chains, which was first suggested by size-exclusion chromatography (Dimroth et al., 
1970). Waldrop et al. described the enzyme as having an overall compressed structure 
divided into three structural domains, which are shown in Figure 1-7 and detailed as 
follows: 
1. The N-terminal domain (also called the A-domain), containing a dinucleotide 
binding motif, has five strands of parallel β-pleated sheets with four α-helices 
on two sides.  The A-domain extends to Ile-103. The A-domain has a minor 
contribution to subunit dimerization. Dividing the A- and B-domains is a 
helix-turn-helix motif, extending from Ala-107 to Ala-126. Both α-helices in 
this region are connected by Asp-115 and are oriented perpendicular to one 
another.  
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2. The C-terminal (or C-domain) is composed of an eight-stranded antiparallel β-
pleated sheet with a three-stranded antiparallel β-pleated sheet and seven α-
helices.  This domain starts with Arg-208, is the largest domain and also 
contains the residues that are most involved in subunit dimerization. The 
initial structure revealed several crystal contacts within surface loops starting 
at alanine 341 and ending at proline 351. 
3. The central (or ATP-grasp) domain consists of two α-helices and three 
antiparallel β-pleated sheets.  This domain, also called the B-domain, 
beginning at Val-131 to Tyr-203, projected outward from the rest of the 
protein in the initial crystal structure of biotin carboxylase, while possessing 
some disordered surface loops. Additionally, the absence of the X-ray 
diffraction data in the glycine-rich region of the polypeptide between the B-
domain and the main body of the protein support the likely presence of a 
highly flexible linker region. A second crystal structure of biotin carboxylase, 
with an active-site mutation and in complex with ATP, was solved to 1.9 Å 
resolution (Thoden et al., 2000a) and showed the B-domain clamped down on 
the body of the enzyme. 
The authors of the second crystal structure described the B-domain as follows: 
“The major conformational change that occurs upon nucleotide binding is a rotation of 
approximately 45° of one domain relative to the other domains thereby closing off the 
active site pocket” (Thoden et al., 2000a); thus, the B-domain was proposed to act as a lid 
that closes down on the active site after the substrates are bound and positioned for 
catalysis. Another group, having solved a crystal structure of wild-type biotin 
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carboxylase in complex with biotin, bicarbonate and Mg-ADP, suggested the biotin 
molecule remains solvent exposed after closure and that biotin carboxyl carrier protein is 
needed to completely close the active site before catalysis (Chou et al., 2009). Results 
from computational chemistry studies suggest that during this closure motion a small 
change in twist angle also occurs (Novak et al., 2009). This large rotation about the hinge 
region was supported by the co-crystal structure (with nucleotide analog 5′-
adenylylimidodiphosphate) of a structurally related enzyme also capable of binding 
nucleotides, carbamyl phosphate synthetase, which revealed a similar closure (Thoden et 
al., 1999; Thoden et al., 2000a). 
 
Figure 1-7. Ribbon Rendering of the Biotin Carboxylase subunit of acetyl-CoA 
carboxylase from E. coli, with one subunit in white and the other in color. (Image 
courtesy of Tyler Broussard) 
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Yet researchers, having solved a crystal structure of biotin carboxylase in the 
presence of ATP analogs, proposed that closing of the hinged region in one subunit 
occurs in concert with the opening of the hinged region in the other subunit, as this 
structure revealed only one ATP analog bound to a single active site at a time (Mochalkin 
et al., 2008). Thus, these same authors suggest the catalytic cycle “flip-flops” between 
active sites. 
The closed conformation of the ATP-bound structure of biotin carboxylase 
exposed that a number of residues converged on the active-site pocket: e.g., Lys-116, 
Lys-159 and Met-169 (Thoden et al., 2000a). According to sequence alignments for 
enzymes having ATP-grasp domains, these three residues appear highly conserved across 
prokaryotic and eukaryotic genomes (Galperin and Koonin, 1997). The results of the 
crystal structure solved by Mochalkin et al. depict Lys-116 and Lys-159 interacting with 
ATP; these interactions are reinforced by the 50-fold (K116Q) and 90-fold (K159Q) 
greater Km reported previously (Sloane et. al. 2001). Bordelon and co-workers suggest 
two neighboring glycine residues (165 and 166) are involved in the binding and 
positioning of ATP, while mutations of these residues appear to result in the 
“misalignment of the reactants for optimal catalysis”; recent crystallographic data also 
support this interaction (Bordelon et al., 2009; Mochalkin et al., 2008).  Moreover, Chou 
and co-workers suggest that two oxygens within the bicarbonate molecule participate in 
ion-pair interactions with the guanidinium of arginine 292. They further explain, one of 
these two bicarbonate oxygens hydrogen bond with the main chain of valine 295 and 
glutamic acid at position 296 likely functions as a general base, extracting the proton 
from the third oxygen of bicarbonate. Subsequently, valine 295 and a tyrosine at position 
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82 are said to be very near the biotin molecule, while an arginine at position 338 may be 
involved in the bonding of hydrogen and stabilizing the carbonyl oxygen in the ureido 
ring of biotin. However, this same arginine most importantly may function to stabilize the 
enolate biotin transition state, as mutation to alanine at this position resulted in an 
inactive enzyme (270-fold decrease in kcat) (Chou et al., 2009). 
Nilsson and co-workers suggested two Mg2+ ions were critical to catalysis by 
alleviating electrostatic repulsion (Nilsson Lill et al., 2008); this, too, has been supported 
by recent crystallographic data (Mochalkin et al., 2008). The Mg2+ ions are coordinated 
to the phosphates of ATP. Specifically, one Mg2+ atom bridges between the α- and γ–
phosphoryl groups of ATP, while the other Mg2+ atom coordinates one β- and one γ-
phosphoryl oxygen of ATP, and glutamic acid residues at positions 274 and 288 play key 
roles in bridging both metal ions, respectively (Mochalkin et al., 2008; Nilsson Lill et al., 
2008). 
Subsequent to the discovery of the three-dimensional structure of biotin 
carboxylase, researchers initially noticed analogous folds between this enzyme and two 
peptide ligases, glutathione synthetase and a peptidoglycan biosynthesis enzyme D-
alanine:D-alanine ligase (Artymiuk et al., 1996). The high similarity in the structure of 
these enzymes is noteworthy, as they have only 11% primary sequence identity, yet they 
catalyze similar reactions. The catalytic mechanism of these three enzymes couples the 
hydrolysis of ATP to the formation of a carbon-nitrogen bond, and each of these 
enzymatic mechanisms includes the same intermediate, an acyl phosphate (Artymiuk et 
al., 1996; Galperin and Koonin, 1997).  
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Not long after these similarities were realized, the structure of carbamyl 
phosphate synthetase was determined (Thoden et al., 1997). This enzyme seems to have 
structural and mechanistic similarities to glutathione synthetase and D-alanine:D-alanine 
ligase; however, it appears most similar to biotin carboxylase, as this enzyme also binds 
ATP and bicarbonate as substrates, and the mechanism evolves through a 
carboxyphosphate intermediate. Collectively, these enzymes represent the first members 
of the ATP-grasp family of enzymes (Galperin and Koonin, 1997). To date, several 
additional enzymes have been added to the ATP-grasp family, including all biotin-
dependent carboxylases; biotin-dependent carboxylase domains of pyruvate carboxylase; 
propionyl-CoA carboxylase; urea amidolyase; tubulin-tyrosine ligase; and three enzymes 
of purine biosynthesis, including glycinamide ribonucleotide synthetase (Wang et al., 
1998), N5-carboxyaminoimidazole transformylase (Thoden et al., 1999), and 
glycinamide ribonucleotide transformylase (Thoden et al., 2000b). 
Catalytic Mechanism of Carboxyltransferase 
The exact mechanism of the transfer of the carboxyl group from carboxybiotin to 
acetyl-CoA in the reaction catalyzed by carboxyltransferase has yet to be elucidated, yet 
the reaction involves an initial abstraction of a proton from the methyl group of acetyl-
CoA with subsequent carboxyl-group transfer from carboxybiotin to acetyl-CoA. Bilder 
et al. describe two glycine residues (206 and 207) that form an oxyanion hole that 
stabilizes the negatively charged ureido enolate that develops within the biotin molecule 
following decarboxylation. Likewise, upon removal of a proton from the methyl group of 
acetyl-CoA, an enolate is created (Waldrop, 2011), thus stabilization of both enolate 
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anions likely contributes to the lowering of the activation energy for the enzyme-
catalyzed reaction. Unfortunately, to date, very few mutagenic studies on 
carboxyltransferase have been done; however, these studies likely will provide 
information toward elucidating the enzymatic mechanism. 
Structure of Carboxyltransferase 
In 2006, the long-awaited initial crystal structure of carboxyltransferase from E. 
coli and S. aureus, shown in Figure 1-8A, was solved and revealed a surprising Zn-
domain not seen in the eukaryotic homolog (Bilder et al., 2006). 
 
Figure 1-8A. Ribbon Rendering of the Carboxyltransferase subunit of Acetyl-CoA 
Carboxylase from E. coli, the beta subunit in white and the alpha subunit in color, with a 
Close-up of Zinc Domain (1-8B). (Images courtesy of Tyler Broussard and Pat Bilder, 
respectively) 
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      (Figure 1-8 continued) 
 
The overall structure of the α2β2 tetramer, or dimeric dimer, of the functional 
enzyme has been referred to as a truncated rectangular pyramid. The structurally 
homologous α- and β-subunits also assume wedge shapes, and a tapering core, initially 13 
Å extending to 23 Å, is presumed to bind the substrates. The quaternary structure 
validated the α2β2 subunit composition suggested by Lane and colleagues (Guchhait et 
al., 1974b), while structural homology to enoyl-CoA hydratase and the presence of an 
oxyanion hole in the β-subunit for CoA-thioenolate stabilization showed that the enzymes 
belong to the crotonase superfamily (Bilder et al., 2006; Gerlt and Babbitt, 2001; Murzin, 
1998).  
The active site of carboxyltransferase most closely resembles the “ridges in 
groves” stacking motif, whereby a six-helix bundle stabilizes the interconnection of 
subunits and forms a catalytic platform. Additionally, two helical domains from the α-
subunit and a Zn-domain from the β-subunit combine to form a porous catalytic lid over 
the catalytic platform. The holes in the catalytic lid have been suggested to act as entry 
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points for substrates. By homology to propionyl-CoA carboxylase from Streptomyces 
coelicolor (Diacovich et al., 2004), it has been suggested that residues G206 and G207 
(near the N-terminus of the eighth alpha helix) and G204 – G205 (in the β-subunit) 
contribute to the formation of a conserved oxyanion holes. These oxyanion holes are 
thought to stabilize the ureido enolate that forms upon decarboxylation of carboxybiotin 
at the 1′ nitrogen by acting as H-bond donors to the carbonyl and enolate intermediate in 
propionyl-CoA carboxylase (Diacovich et al., 2004); a similar function is expected of the 
conserved residues in carboxyltransferase. The overall fold, not surprisingly, is similar to 
that of carboxyltransferase from yeast (Zhang et al., 2003) and S. coelicolor (Diacovich 
et al., 2004). However, when the gene for the β-subunit of E. coli carboxyltransferase 
was cloned and sequenced more than 20 years ago (Bognar et al., 1987), the authors 
noted the tandem C-X-X-C sequences separated by 15 residues near the amino terminus 
and hypothesized that the protein had metal-binding domains homologous to nucleic 
acid-binding proteins.  
The crystal structures of carboxyltransferase from S. aureus and E. coli, along 
with X-ray fluorescence studies, have confirmed this prediction. The metal atom is zinc, 
and it forms part of a zinc motif that is unique to bacterial carboxyltransferase (Figure 1-
8, B). A space-filling representation reveals that the Zn-domain, specifically classified as 
an atypical zinc ribbon, forms part of a saddlelike structure, and an electrostatic surface-
potential rendering shows that the inner face of the zinc-finger domain has an 
electropositive surface potential, while most of the protein has an electronegative surface 
potential. Sequence alignment of the primary sequence of this zinc finger (versus 
orthologous enzymes from Eubacteria, algae, plants, and animals) suggests the existence 
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in prokaryotes alone. This zinc ribbon is thought to most closely resemble those of 
ribosomal proteins (Bilder et al., 2006); a brief explanation of zinc fingers in the context 
of carboxyl transferases is provided in the second section of this introduction. 
Regulation of Acetyl-CoA Carboxylase  
Because acetyl-CoA carboxylase acts as the committed step in fatty-acid 
biosynthesis in most kingdoms (Cronan and Waldrop, 2002), excepting the Archaea and 
some mycoplasmas (McAllister et al., 2006), it is tightly regulated. The product of the 
reaction catalyzed by acetyl-CoA carboxylase (malonyl-CoA) becomes the substrate for 
the second enzyme in the pathway (fatty-acid synthase) in an energetically costly reaction 
and should be tightly regulated. As such, different mechanisms of regulation exist in 
prokaryotes versus eukaryotes. Here, the two processes are briefly explained. 
In E. coli, the genes for biotin carboxylase and biotin carboxyl carrier protein are 
co-transcribed as the accBC operon (Li and Cronan, 1992a). However, this gene 
arrangement is not universal among prokaryotes, as several gram-positive bacteria 
possess the acc genes as clustered with the fatty-acid synthetic genes (Cronan and 
Waldrop, 2002). Researchers first noticed that bacteria harboring high copy number 
plasmids (10 – 50 plasmids per cell) containing the accBC operon did not overproduce 
proteins commensurate with the plasmid copies (Li and Cronan, 1993). They also 
proposed that the replacement of the native promoter with a heterologous promoter 
produced a “straightforward dependence on copy number,” as seen in protein production. 
The results suggest the requirement for a transcriptional activator or that these proteins 
repress their own synthesis (Cronan and Waldrop, 2002). Interestingly, biotin carboxyl 
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carrier protein was reported to be capable of suppressing transcription of the accBC 
operon, suggesting an autoregulatory feedback mechanism of transcriptional control 
(James and Cronan, 2004).  
However, Li and Cronan suggest an alternative regulatory mechanism exists in 
the expression of carboxyltransferase in E. coli, and this process remains poorly 
understood (Li and Cronan, 1993).  They agree that both genes for carboxyltransferase 
reside in complex gene clusters that are part of vital biosynthetic processes (5'-ORF17-
lpx4-lpxB-ORF23-polC-accA-3' and 5'-ubxI-hisTdedA- accD-folC-dedD-dedE-purF-
dedF-argT-3', respectively) and are likely cotranscribed. Interestingly, I reported the 
specific binding of carboxyltransferase to mRNA encoding the α and β subunits (Meades 
et al., 2010). This information may help to explain the vastly different expression levels 
observed between accBC and accA-accD-specific mRNA reported (Li and Cronan, 
1993). These same authors reported a high copy number of accA-accD-specific mRNA 
was detected in bacterial strains harboring the high copy number plasmid. This may be 
suggestive of a translational regulatory mechanism; thus, it remains possible for the two 
operons containing the genes for accA-accD to be expressed at a high level, while high 
concentrations of carboxyltransferase shift equilibrium toward enzyme:mRNA complex 
and translation suppression. Aside from regulation for acetyl-CoA carboxylase synthesis, 
other mechanisms for regulation exist, i.e. the regulation of enzymatic activity.  
Though acetyl-CoA carboxylase was observed to be inhibited in vitro and thought 
to be regulated by high levels of (p)ppGpp, a molecule said to accumulate under 
conditions of amino-acid starvation, it since has been realized that this process is 
physiologically irrelevant (Cronan and Waldrop, 2002). However, acyl carrier protein 
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serves as the hub for the pathway, as it tethers the nascent fatty acyl chain until it 
dissociates as palmitic acid. In 2001, Davis and co-workers, while studying E. coli, 
suggested acylated derivatives of this protein partially inhibit acetyl-CoA carboxylase. 
Though the inhibition never reached 100%, E. coli acyl carrier protein was specifically 
required, as acylated derivatives of the homologous protein from spinach had no effect. 
Interestingly, acyl chain lengths between C6 and C20 had equal inhibitory effect, and 
acyl carrier protein was reported to inhibit the overall reaction but not either partial 
reaction. It is hypothesized that this feedback mechanism acts to conserve energy and as a 
key metabolic intermediate (acetyl-CoA) in the presence of sufficient levels of fatty acid 
(Davis and Cronan, 2001). 
In mammals, two isoforms of acetyl-CoA carboxylase exist: ACC1 and ACC2 
(Abu-Elheiga et al., 1995; Widmer J et al., 1996); the former is primarily expressed in 
lipogenic tissues, i.e. kidney and liver, and the latter is expressed in muscle. Abu-Elheiga 
and co-workers have shown that ACC1 is involved in fatty-acid biosynthesis and that 
ACC2 is involved in inhibiting fatty-acid oxidation (Abu-Elheiga et al., 1997; Saddik et 
al., 1993).  Specifically, ACC2 increases levels of malonyl-CoA that inhibit carnitine 
palmitoyl transferase-1 and terminate the delivery of fatty acids for oxidation (Abu-
Elheiga et al., 1997; Saggerson, 2008).     
Mammalian acetyl-CoA carboxylase can be regulated by several mechanisms. In 
fasting organisms, acetyl-CoA carboxylase expression is low, yet it increases upon 
feeding (Iritani, 1992). Mabrouk and co-workers reported acetyl-CoA carboxylase 
isolated from rat livers after an insulin bolus had higher enzymatic activity; whereas, the 
enzyme had a lower activity after administration of glucagon, or epinephrine (Mabrouk et 
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al., 1990). A high degree of polymerization of acetyl-CoA carboxylase has been found to 
correspond to an increase in enzyme activity, and dephosphorylation by [acetyl-CoA 
carboxylase]-phosphatase 2 leads to protomer polymerization (Thampy and Wakil, 
1988). Conversely, one mechanism involved in the short-term reduction of the catalytic 
activity of acetyl-CoA carboxylase is phosphorylation and subsequent depolymerization; 
the enzyme AMP-activated protein kinase (SNF1 gene product in yeast) phosphorylates 
acetyl-CoA carboxylase on multiple serine residues (Brownsey et al., 2006; Mitchelhill et 
al., 1994; Woods et al., 1994). Another form of regulation in the human ACC1 gene 
occurs via the expression of alternative exons. Three promoters (PI, II and III) for the 
enzyme have been described, suggesting the possibility of three isoforms (Kim, 1997; 
Mao et al., 2003). ACC1 is constitutively and highly expressed, PII is regulated by the 
thyroid hormone, Triiodothyronine (T3), and PIII plays a critical role during lactation 
needed for baby development (Mao et al., 2003). 
Acetyl-CoA Carboxylase in Agriculture and Medicine 
Acetyl-CoA Carboxylase as a Herbicide Target 
Molecules from the chemical classes aryloxyphenoxypropionates (AOPPs), 
cyclohexanediones (CHDs) and phenylpyrazolin inhibit acetyl-CoA carboxylase and are 
used as selective herbicides on some rice, wheat and grass weeds (Burton et al., 1987; 
Walker et al., 1988). Though variations in uptake, translocation, detoxification, and 
activation contribute to herbicide selectivity in plants, the greatest determinant of 
susceptibility lies in the type of the plant’s acetyl-CoA carboxylase (Harwood, 1988). 
Most plants contain two forms of acetyl-CoA carboxylase, namely prokaryotic and 
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eukaryotic forms. The eukaryotic form of acetyl-CoA carboxylase is inhibited by these 
herbicides, while the prokaryotic form is not. Plants lacking the prokaryotic form of the 
enzyme are susceptible to these inhibitors (Konishi and Sasaki, 1994). 
Inhibition studies of alloxydim, sethoxydim and clethodim, examples of the CHD 
chemical class, and eukaryotic acetyl-CoA carboxylase showed half-maximal values 
ranging from 0.12 to 5.0 µM (Rendina and Felts, 1988); whereas, the R isomer of 
fluazifop has a half-maximal value of 4 µM (Walker et al., 1988). These same authors 
noted a decrease in the chain length of fatty acids in the presence of fluazifop. These 
investigators also showed specifically that the carboxyltransferase half-reaction was the 
target of these herbicides (Rendina et al., 1989; Rendina and Felts, 1988; Walker et al., 
1988). More recently co-crystal structures were reported for yeast acetyl-CoA 
carboxylase and haloxyfop (Zhang et al., 2004), tepraloxydim (Xiang et al., 2009), and 
pinoxaden (a phenylpyrazolin) (Yu et al., 2010) and proved herbicide binding at the 
carboxyltransferase active site. 
Some plants that were once sensitive to these herbicides have become resistant. 
Plant insensitivity is conferred by the following mechanism: (1) enhanced herbicide 
detoxification (De Prado et al., 2004) and (2) point mutations in isoforms of acetyl-CoA 
carboxylase (De Prado et al., 2004; Alarcon-Reverte and Moss, 2008; Parker et al., 
1990), which were described by one author as being controlled by a single dominant or 
semi-dominant nuclear gene (Price et al., 2003). Researchers studying acetyl-CoA 
carboxylase that was either inherently resistant or that developed insensitivity to these 
herbicides described a critical isoleucine-to-leucine substitution (Zagnitko et al., 2001) 
and report that some insensitive forms of the enzyme bind the herbicide in a co-operative 
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manner (Price et al., 2003). The utility of these herbicides, as well as the resistance 
mechanisms, warrant future investigation and inhibitor design. 
The United States’ Obesity Epidemic 
The U.S. Centers for Disease Control and Prevention reported (Behavioral Risk 
Factor Surveillance System and The Morbidity and Mortality Weekly Report, Centers for 
Disease Control, 2006), “During the past 20 years there has been a dramatic increase in 
obesity in the United States,” and, “In 2007, only one state (Colorado) had a prevalence 
of obesity less than 20%. Thirty states had prevalence equal to or greater than 25%; three 
of these states (Alabama, Mississippi, and Tennessee) had a prevalence of obesity equal 
to or greater than 30%.” Having surpassed the threshold for epidemic status, finding ways 
to treat obesity to avoid associated sequela, e.g. metabolic syndrome, hypertension, 
hyperlipidemia, type II diabetes, cardiovascular disease and cancer, is paramount. The 
vital role of acetyl-CoA carboxylase in long-chain fatty-acid synthesis makes it an 
obvious target for therapeutic intervention in the context of a variety of diseases. 
Consequently, it has been implicated as having a role in the treatment of obesity 
(Magnard et al., 2002), and inhibiting acetyl-CoA carboxylase in humans may provide 
for medically induced weight loss. 
Acetyl-CoA Carboxylase in Chronic Diseases 
Acetyl-CoA carboxylase has been considered a therapeutic target in the treatment 
of cardiovascular risk factors (Harwood et al., 2003), cancer (Magnard et al., 2002) and 
obesity (Levert et al., 2002). Proof of concept for this theory came indirectly as one study 
demonstrated a reduction in body weight in mice treated with fatty-acid synthase 
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inhibitors (Loftus et al., 2000).  Though one should anticipate fat loss when fatty-acid 
synthase is inhibited, an interesting twist came from the proposed cause of the weight 
loss. Researchers observed that these mice had reduced appetite and an increase in 
malonyl-CoA, and the researchers suggested that excess malonyl-CoA is an appetite 
suppressant (Lane and Cha, 2009). In a second study, mice lacking an isoform of acetyl-
CoA carboxylase (ACC), specifically ACC2 (previously referred to as ((H))ACC-β), as a 
result of genetic engineering, had lower levels of malonyl-CoA and were observed to lose 
weight despite greater food intake than control mice, and these mice were reported to 
have normal life spans (Abu-Elheiga et al., 2001). In the absence of malonyl-CoA, fatty-
acid oxidation outpaces fatty-acid synthesis, and fats are mobilized from hepatic and 
adipose stores to muscle cells. Taken together, there appears to be a connection in 
abnormal malonyl-CoA levels and weight loss.  An unequivocal connection between 
acetyl-CoA carboxylase and obesity exists, and it is reasonable to expect, in the near 
future, anti-obesity therapy to target acetyl-CoA carboxylase.  
The potential for improving the health of patients with cardiometabolic risk 
factors, because of diabetes and metabolic syndrome, by inhibiting ACC2 shows promise. 
In another knockout murine model, the results of mice treated with isozyme-specific 
antisense oligonucleotides or with isozyme-nonselective acetyl-CoA carboxylase 
inhibitors have demonstrated the potential for treating metabolic syndrome (Harwood, 
2003). Interestingly, isozyme-nonselective acetyl-CoA carboxylase inhibitors seem to 
show the most therapeutic potential (Corbett et al., 2007).  This work has underscored the 
valid role of acetyl-CoA carboxylase in the treatment of noninfectious diseases. 
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Need For New Antibiotics — Acetyl-CoA Carboxylase a Valid Target 
The incidence of multidrug-resistant bacterial pathogens is rising at an alarming 
rate (Chen et al., 2009).  Previously limited to hospitals, common infections from 
antibiotic-resistant, gram-positive (S. aureus and Streptococcus pneumoniae) and gram-
negative (E. coli and Pseudomonas aeruginosa) bacteria have become common in 
community settings as well (Menichetti, 2005). Clinicians remain concerned about the 
emergence of the “ESKAPE” pathogens (Enterococcus faecium, S. aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, P. aeruginosa, and Enterobacter species).  The 
acronym reflects the fact that these bacteria represent the majority of nosocomial 
infections and effectively elude the antibacterial drug’s mechanism of action (Boucher et 
al., 2009). Moreover, strains of gram-positive pathogenic bacteria are proving resistant to 
our “last line of defense,” namely vancomycin. Here again, strains of S. aureus have 
emerged resistant (Menichetti, 2005). Over the latter third of the last century, there was a 
steep decline in the rate at which new antibiotics became available, and the effectiveness 
of subsequent-generation antibiotics is shorter lived than parent, presently ineffective 
antibiotics; thus, novel classes of both antibiotics and enzyme targets should be 
considered. 
Prior to the year 2000, the last novel class of antibiotics was trimethoprim, 
released in 1968, and, though new antibiotics continued to be released, most were 
permutations of natural products or chemical modifications of previously discovered 
classes of drugs (Powers, 2004). Fortunately, in 2003 the United States Food and Drug 
Administration approved the use of daptomycin for treating complicated skin and soft-
tissue infections from gram-positive bacteria (Kern 2006). This molecule represents the 
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first in a new class of antibiotics called the cyclic lipopeptides and is described as having 
a cationic antimicrobial peptide-like mechanism (Ernst et al., 2009), yet the mechanism 
of action for this antibiotic is not completely understood. It is proposed to bind to the 
cytoplasmic membrane via a calcium-dependent insertion of the hydrophobic tail and 
oligomerization. Subsequently, the membrane is disrupted, resulting in efflux of 
potassium, arrest of nucleic acid and protein synthesis and cell death (Canepari et al., 
1990; Silverman et al., 2003; Steenbergen et al., 2005; Shah, 2005). However, Ernst et al. 
describe MprF, a bacterial defensin resistance protein, as having a critical function in 
microbe virulence and being involved in resistance to daptomycin. Unfortunately, to date 
drug-development strategies have included limited cellular targets; thus, it has become 
imperative to design pharmaceuticals against additional metabolic processes.   
To expand the cellular targets of antibiotics, bacterial enzymes involved in fatty-
acid synthesis (Type II) have materialized as important targets for drug design (Campbell 
and Cronan, 2001; Heath et al., 1998; Marrakchi et al., 2002; Zhang et al., 2006). Two 
such examples of inhibitors designed to target a bacterial FAS-II enzyme are the 
antitubercular drugs isoniazid and ethionamide, which inhibit enoyl-ACP reductase.  
Enoyl-ACP reductase reduces the trans double bond between positions C2 and C3 of a 
fatty acyl chain linked to the acyl carrier protein.  This reaction is essential in mycolic 
acid (virulence factor) biosynthesis (Banerjee et al., 1994; Heath et al., 1998). Other 
antibiotics, such as cerulenin and thiolactomycin (also classified as an antifungal and 
antimalarial, respectively), inhibit beta ketoacyl-ACP synthase, which is involved in 
FAS-II chain condensation (D’Agnolo et al., 1973; Hayashi et al., 1983). Unfortunately, 
the structures of enoyl-ACP reductase and ketoacyl-ACP synthase are highly variable 
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across species, and high variability is thought to result in weaker binding and reduced 
effectiveness in some species. Thus, these antibiotics are considered narrow spectrum 
with limited advantages. 
In contrast with the high sequence and structure variability seen in the fatty-acid 
biosynthesis gene products, acetyl-CoA carboxylase is widely conserved among bacterial 
species and may be a better antibiotic target. Interestingly, an inhibitor of one of the 
many isoforms of acetyl-CoA carboxylase, namely AccD6, in Mycobacterium has been 
described (Kurth et al., 2009). Additionally, andrimid and moiramide, a class of natural 
products with a pseudopeptide pyrrolidinedione backbone, (Freiberg et al., 2004; 
Pohlmann et al., 2005) inhibit the carboxyltransferase component, while a 
pyridopyrimidine inhibitor targets the biotin carboxylase component (Miller et al., 2009); 
thus, theoretically these antibiotics would have a synergistic therapeutic effect.  
Andrimid is an antibiotic produced by Pantoea agglomerans (Liu et al., 2008), 
and it directly targets the accD gene product (β-subunit of carboxyltransferase) in acetyl-
CoA carboxylase. Resistance to andrimid in P. agglomerans (and likely Vibrio cholera) 
is conferred via horizontal gene transfer or gene duplication of AccD. The duplicated 
AccD, called AdmT, is actually part of the andrimid biosynthesis gene cluster and has 
nearly 90% sequence similarity when compared to AccD. The AdmT gene product, when 
mixed with the alpha subunit of carboxyltransferase, is capable of catalyzing the same 
reaction as wild-type carboxyltransferase, and this hybrid enzyme has similar kinetic 
parameters as the wild-type enzyme. Researchers have determined a critical active-site 
residue (position 203) that contributes to increased resistance. Specifically, a methionine-
to-leucine change at this position in the wild-type beta subunit of carboxyltransferase 
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increases resistance to andrimid; while, in AdmT, a leucine-to-methionine change 
increases sensitivity to the antibiotic. Methionine or leucine in this position are thought to 
be important in the interaction with andrimid or the substrate acetyl-CoA, respectively 
(Liu et al., 2008). 
Miller and colleagues, while searching for new antibiotics, used a library 
containing ~1.6 million compounds of mostly ATP-competitive ligands -- initially 
intended to discover inhibitors for eukaryotic protein kinases (Miller et al., 2009). A 
whole bacterial cell screening assay was deployed and identified a series of 
pyridopyrimidines that proved to be bactericidal against E. coli, Haemophilus influenzae, 
and Moraxella catarrhalis. A biological macromolecular biosynthesis assay revealed 
fatty-acid synthesis was targeted by this inhibitor, and the interaction with biotin 
carboxylase was confirmed using isothermal titration calorimetry and surface-plasmon 
resonance (Miller et al., 2009). A co-crystal structure provided evidence that the inhibitor 
binds to the ATP-binding site in biotin carboxylase, and a mutation (I437T) in the gene 
for biotin carboxylase from E. coli conferred resistance to the inhibitor. Interestingly, 
when this inhibitor was originally screened as a potential eukaryotic protein kinase 
inhibitor, it was found to be only weakly active toward Src eukaryotic protein kinase. 
This inhibitor has at least a 70-fold lower affinity for Src protein kinase and eukaryotic 
acetyl-CoA carboxylase. Moreover, this inhibitor was found to work synergistically when 
administered with another inhibitor of fatty-acid biosynthesis, the antiseptic triclosan 
(Miller et al., 2009). This work may inspire researchers to consider other bacterial ATP-
/GTP-utilizing enzymes as potential antibiotic targets and identify hit molecules similarly 
(Walsh and Fischbach, 2009). 
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Based on three-dimensional shape and electrostatic complementarity, researchers 
virtually screened 2.2 million compounds for inhibition of biotin carboxylase and 
selected 525 for a high-through screening assay.  A second experiment more carefully 
probed the active site of the enzyme with 5,200 structurally diverse, small molecules via 
saturation transfer difference NMR in addition to the acetyl-CoA carboxylase assay. This 
assay revealed weak, yet ligand-efficient, binding fragments, and six molecules with an 
IC50 less than 95 µM were found. X-ray crystallography provided visualization of binding 
modes for the higher-affinity compounds and fragments, while overlays of several co-
crystal structures exposed binding trends and more effective inhibitors were synthesized. 
Iterative cycles of structure-based drug design involved fragment growing, merging and 
morphing on successive fragment costructures. This process improved the potency of the 
inhibitors up to 3000-fold, with the lead compounds being a series of amino-oxazoles 
(Mochalkin et al., 2009). 
Researchers from Schering-Plough used Affinity-Selection Mass Spectrometry to 
identify a series of low-molecular-weight benzimidazoles that bind biotin carboxylase. 
This series of molecules also inhibit the enzyme with an IC50 in the low µM range, and 
the X-ray co-crystal structure with this inhibitor was solved and revealed important 
interactions between the inhibitor and the biotin carboxylase ATP-binding site. Through 
the use of Computer Aided Structure Based Drug Design and parallel synthetic 
approaches, these workers were able to optimize inhibitor binding and generate a potent 
and selective inhibitor of biotin carboxylase with antibacterial activity, having a 360-fold 
improvement in enzyme inhibition (IC50 of 20 nM) compared with the initial compounds 
(Cheng et al., 2009).  
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CHAPTER 1 
INTRODUCTION 
SECTION 2 
 
 
Some Metabolic Enzymes Bind Nucleic Acids  
Recently, it has been realized that metabolic enzymes, which are not traditionally 
considered components of transcription or translation, can control gene expression 
(Commichau and Stulke, 2008). This secondary function for these enzymes was coined 
by Jeffery in 1999 as “moonlighting” and is thought of as a fossil from the RNA world 
(Jeffery, 1999; Kyrpides and Ouzounis, 1995; Ciesla, 2006). One author suggested the 
logic in this mechanism of regulation lies in the fact that proteins are the “most informed 
molecules in the cell,” regarding concentration of metabolites, making these enzymes 
ideal candidates for either controlling other gene regulators or regulating gene expression 
directly (Commichau and Stulke, 2008). There are many examples of eukaryotic 
metabolic moonlighting enzymes (Hall et al., 2004); however, there are far fewer in 
prokaryotes.  In 1995, Kyrpides and Ouzounis noted 16 examples from various organisms 
(Kyrpides and Ouzounis, 1995). Since then, the list has grown, and a non-exhaustive 
compilation, including 25 examples, is provided (Table 1-1), with more detail on a few 
representative examples.  
Though several moonlighting enzymes were listed, here a few well-understood 
prokaryotic and eukaryotic examples from differing metabolic pathways are briefly 
highlighted.  
• In prokaryotes: 
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o BirA is capable of synthesizing biotinyl-5′-AMP, transferring biotin to a lysine 
residue of the biotin carboxyl carrier protein and repressing biotin biosynthesis 
via site-specific DNA binding (Xu et al., 1995). The central domain of BirA is 
catalytic, and the N-terminal domain binds DNA via a helix-turn-helix structural 
module (Rodionov et al., 2002). 
o The DNA-binding domain PutA can be expressed and purified without the 
enzymatic domain and still bind DNA (Ostrovsky de Spicer and Maloy, 1993). 
In the wild-type enzyme, the inactive form binds the promoter regions of related 
genes and acts as a repressor; yet after a proline-dependent reduction of FAD 
and a concomitant conformational change in the protein, the enzyme 
translocates to the membrane for catalytic function (Zhang et al., 2004b).  
o Iron regulatory protein 1 (also known as citrate dehydrogenase) catalyzes the 
conversion of citrate to isocitrate in the tricarboxylic acid cycle and serves as a 
lone example of a trigger enzyme with RNA-binding ability (Beinert and Kiley, 
1996). In the presence of iron, this enzyme adopts a compact conformation; yet, 
in the absence of iron, the enzyme assumes an open conformation capable of 
binding mRNA. 
• In eukaryotes: 
o The transcription factor from Drosophila, eyes absent, is known to have Tyr 
phosphatase activity and the ability to autocatalytically self-dephosphorylate 
and belongs to the haloacid dehalogenases family of enzymes (Tootle et al., 
2003).  
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o An enzyme known to bind DNA, a cysteine protease called LeCp, also has dual 
functions. In the cytoplasm, this enzyme functions as a protease; however, upon 
the binding of a small ubiquitin-related modifier protein, LeCp enters the 
nucleus and acts as a transcription factor. Specifically, in tomato plants this 
enzyme’s secondary function is to induce LeAcs2 (1-aminocyclopropane-1-
caboxylic acid synthase) expression.  
o The mitochondrial enzyme Arg5,6 is involved in catalyzing two key steps in the 
biosynthesis of ornithine, which is a precursor to arginine (Hall et al., 2004). 
Ilv5p binds DNA and catalyzes a reaction in branched-chain amino-acid 
biosynthesis (Bateman et al., 2002a).   
o Interestingly, the binding of DNA and the enzymatic activity of Ilv5p are 
independent of one another, as either the DNA-binding domain or the enzymatic 
domain can be inactivated without affecting the activity of the other domain 
(Bateman et al., 2002b). 
o This thesis describes the dual functions of carboxyltransferase, one of which is 
involved in binding nucleic acids, via a zinc finger. In the next section, the 
catalytic and structural contribution of protein zinc fingers are considered as is 
their interaction with nucleic acids. 
Table 1-1. Examples of Nucleic-Acid Binding Metabolic Enzymes 
Name Organism Function Nucleic 
Acid 
Substrate 
Reference 
Eukaryotic DNA binding     
LDH Human Fermentation DNA Perucho, et 
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al., 1980 
hRoDH-E2 Human Retinol 
dehydrogenase 
DNA Markova et 
al., 2006 
Arg 5, 6 Yeast Amino acid 
synthesis 
ds-DNA Hall et al., 
2004 
Eyes absent  Fly Protein tyrosine 
phosphatase 
ds-DNA Tootle et al., 
2003 
HXK Yeast Glycolysis, 
reaction 1 
ds-DNA Prior et al., 
1993 
LeCp Plants Protease ds-DNA Matarasso et 
al., 2005 
NDP kinase Human NTP synthesis ds-DNA Postel et al., 
1993 
Fatty Acid Synthase Yeast Fatty acid 
synthesis 
ss- and ds-
DNA 
Kaslan and 
Heyer, 1994 
C1-THFS Yeast Amino acid 
synthesis 
ss-DNA Wahls et al., 
1993 
G3PD Human Glycolysis, 
reaction 6 
DNA, 
(t)RNA 
Perucho, et 
al., 1980 
Ilv5p Yeast Amino acid 
synthesis 
mt-DNA Bateman et 
al., 2002a 
Aco1p Yeast Citric acid cycle mt-DNA Chen et al., 
2005 
Eukaryotic RNA binding     
1, 4-α-gBE Rabbit Glycogen 
biosynthesis 
RNA Korneeva et 
al., 1979 
Catalase Rat H2O2 
breakdown 
Cognate 
mRNA 
Clerch et al., 
1991 
DHFR	   Human Nucleotide  Cognate  Chu et al.,  
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TS  
 
Human 
 
Thymine 
synthesis 
 
Cognate 
mRNA 
 
Chu et al., 
1993 
GDH Cow Amino acid 
synthesis 
Noncognate 
RNA 
Preiss et al., 
1993 
IDH  
 
Yeast Citric acid 
cycle, reaction 
3 
Noncognate 
RNA 
Elzinga et 
al., 1993 
Thiolase Fly Fatty acid 
metabolism 
Noncognate 
RNA 
Nanbu et al., 
1993 
Enolase Yeast Glycolysis tRNA Entelis et 
al., 2006 
Prokaryotic DNA binding     
BirA Bacteria Biotin synthesis ds-DNA Cronan, 
1989 
PutA Bacteria Amino acid 
catabolism 
ds-DNA Ostrovsky 
de Spicer 
and Maloy, 
1993 
NadR Bacteria NAD 
biosynthesis 
ds-DNA Raffaelli et 
al., 1999 
PepA Bacteria Aminopeptidase ds-DNA Charlier et 
al., 2000 
Prokaryotic RNA binding     
Aconitase (IRP1) Bacteria (and 
humans) 
Citric acid 
cycle, reaction 
2 
IRE 
(mRNA) 
Beinert and 
Kiley, 1996 
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The Types and Functions of the Zinc Fingers 
In 1869, while working with Aspergillus niger, Raulin first demonstrated zinc to 
be essential for growth (Raulin, 1869). More recently, the metal has been shown 
necessary for growth, development and differentiation (Vallee et al., 1986), and it is 
present in all domains of life. Zinc is ubiquitous in all tissue types of higher organisms, 
and the element typically exerts a catalytic, cocatalytic or structural function while bound 
to proteins (McCall, et al., 2000). Though zinc atoms more often have a structural 
function, there are more than 300 zinc-containing enzymes known, with examples 
coming from the six classes of enzymes (Vallee and Auld, 1990).  
The catalytic role of zinc has been described in the first known zinc 
metalloenzyme, carbonic anhydrase II, discovered by Keilin and Mann in bovine blood  
(Keilin and Mann, 1940). In most cases, the zinc ion in metalloenzymes contains a filled 
d orbital and acts as a Lewis acid, accepting a pair of electrons (Williams, 1987). The 
binding geometry most often observed is a distorted tetrahedron, and the zinc ion 
coordinates three or four amino-acid residues (Grishin, 2001).  
The structural role of the zinc atom is to bind amino-acid side chains, specifically 
the nitrogen of histidine, the oxygen of aspartate or glutamate and the sulfur of cysteine 
(Gregory et al., 1993), leading to the formation of discrete structural domains that are 
self-stabilizing and that fold autonomously relative to the rest of the protein (Klug and 
Schwabe, 1995). These structural domains are called motifs, as they have been observed 
in different polypeptides, and they often confer a related function.  The motif refers only 
to the small region of the protein and is considered a supersecondary structure, as 
opposed to a global conformation or tertiary structure. 
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The zinc finger, as a supersecondary structure, is capable of interacting with an 
assortment of ligands that includes proteins, lipids (Grishin, 2001) and small molecules, 
while functioning in a variety of biological processes, encompassing replication and 
repair, transcription and translation, metabolism and signaling, cell proliferation and 
apoptosis (Krishna et al., 2003). Over the next few paragraphs, zinc domains are 
described with a focus on their main function of nucleic-acid binding; special attention is 
paid to the structure most analogous to the zinc finger of carboxyltransferase. 
 Zinc fingers often are lumped with other DNA-binding motifs, i.e. helix-turn-
helix and leucine-zipper, as having the capacity to recognize specific DNA sequences and 
facilitate DNA binding by regulatory proteins. Zinc fingers were so named because the 
individual modules “grip” the DNA (Klug and Schwabe, 1995) like fingers, while the rest 
of the protein serves as the analogous “hand.” 
The first zinc finger discovered was part of “factor A,” or TFIIIA, a transcription 
factor from Xenopus laevis, and contained pairs of cysteines and histidines bound by a 
single zinc atom. The TFIIIA zinc finger is a Cys2His2 zinc finger binding one zinc atom. 
The residues that ligate zinc are spaced as follows: Cys-X(2 or 4)-Cys-X12-His-X3-His 
(Miller et al., 1985). Since then, the discovery of other types of zinc fingers has followed, 
but past methods of classification have focused on the types of residues that bind zinc or 
the geometry of the interactions. The most recent method of classification focuses on the 
protein backbone surrounding the zinc finger; specifically, Krishna and co-workers have 
emphasized fold groups and described the conformation of the protein backbone within 
the domain as a newer method for grouping zinc fingers (Krishna et al., 2003). A 
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reproduction of their table listing zinc finger classes and some zinc finger proteins is 
provided (Table 1-2).  
Table 1-2. List of Structural Classes of Zinc Fingers Highlighting Metal-Binding 
Residues  
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           It is important to note that the most common function of the zinc atom in the zinc 
fingers is to provide regional secondary structure instead of directly binding nucleic 
acids. Zinc fingers often interact with the major groove of DNA while wrapping around 
both strands. Specific sequence recognition is determined via the side chains of several 
amino acids, which are typically part of an α–helix adjacent to the zinc atom (Iuchi, 
2005). Zinc-finger domains interact with DNA by forming hydrogen bonds and 
hydrophobic interactions with nucleotide bases and often recognize specific triplets of 
DNA sequences (Krishna et al., 2003). Moreover, most sequence-specific DNA-binding 
proteins contain two or three tandem zinc fingers, if no other alternative DNA-binding 
domains are present.  In the case of the single zinc finger, low-affinity or nonspecific 
binding is expected, yet the possibility remains for the necessity of an adaptor protein(s) 
to facilitate sequence specific high-affinity DNA binding (Iuchi, 2005). 
Krishna and co-authors provided copious information on the eight fold groups of 
zinc-finger proteins; however, this dissertation will provide detail on the zinc ribbon fold 
group that Bilder and co-workers suggest best resembles the zinc domain of 
carboxyltransferase subunit of acetyl-CoA carboxylase from E. coli and S. aureus (Bilder 
et al., 2006). Interestingly, Krishna and co-workers describe this group as containing the 
most numerous examples of zinc fingers; however, aside from the metal-binding 
residues, this group has minimal sequence conservation and is structurally variable.  
The four residues binding zinc are paired, with each pair forming a zinc-knuckle, 
and each zinc atom bound by two knuckles; however, the four ligands need not be 
cysteine, and the metal atom may be iron. Each zinc-knuckle is made of β-hairpins, 
usually two to four residues in length, and a variable third β-strand, if present, may 
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contribute hydrogen bonding with one of the other β-strands. This fold group has been 
further subdivided into left- and right-handed zinc ribbons, based on the order of the zinc 
ligands as positioned in a plane of the tetrahedron after orientation with the primary 
hairpin above the secondary hairpin. Krishna and co-workers have subdivided the zinc 
ribbon fold group; the subdivisions are called families and include:  
1. Classical zinc ribbons with the following subfamilies: transcription factors, 
primases, polymerases, topoisomerases and ribosomal proteins. 
2. Rubredoxin-like fold, which binds zinc via a pair of cysteines and a pair of 
histidines. In this family, each amino acid pair coordinates a separate zinc atom. 
3. Single-stranded DNA-binding protein ADDBP. 
4. Rubredoxin-like domains in enzymes that “function as interaction modules, e.g. to 
provide a ‘lid’ for the enzyme's active site.” Examples include: aminoacyl tRNA 
synthetase, silent information regulator (abbreviated SIR2) and adenylate kinase.  
The zinc finger in carboxyltransferase is thought to be most structurally analogous 
to the zinc fingers of proteins in the classic zinc ribbon family; thus, this subgroup is 
further described. The classic zinc-ribbon family is defined by having a longer secondary 
hairpin and longer three-stranded β-sheet when compared with other zinc-ribbon proteins. 
Within the classic zinc-ribbon family, there are several subfamilies. One of the 
subfamilies is called the transcription factors, and this group includes transcription 
elongation factor SII (e.g. TFIIS and 1tfi), the transcription initiation factor TFIIB (e.g. 
1pft and 1dl6) and the N-terminal 12 kDa fragment of DNA primase (e.g. 1d0q). Another 
subfamily of the classic zinc-ribbon subgroup is the polymerase proteins subfamily. It 
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includes Rpb1, Rpb2, Rpb9 and Rpb12; however, the zinc domains of these proteins are 
more variable in length. One more subfamily of the classic zinc ribbons consists of the 
ribosomal proteins, such as the 50S ribosomal proteins L44E (chain 2 of 1jj2), L37E 
(chain Z of 1jj2), and L37Ae (chain Y of 1jj2) from Haloarcula marismortui. Examples 
of proteins within this subfamily are thought to be the closest structural match to 
carboxyltransferase (Krishna et al., 2003; Bilder et al., 2006). 
The Tetracyclines, Additional Inhibitors of Carboxyltransferase  
Chapter 3 covers tetracycline inhibiting carboxyltransferase, and background 
information on tetracycline, including a brief history, follows. Though we consider 
antibiotics to be less than a century old, mankind has used these natural products for 
much longer. The presence of tetracyclines, as discovered by ultraviolet microscopy in 
1,400-year-old bone found in what is present day Sudan, suggests that man has long since 
coexisted with microbes and benefitted medicinally from the family of secondary 
metabolites collectively known as tetracyclines (Armelagos et al., 2001). In 1947, 
Benjamin Minge Duggar first isolated tetracycline from Streptomyces aureofaciens, 
naming it Aureomycin (Duggar, 1948). Around the same time, Pfizer described a 
molecule with similar melting point, solubility, pH range stability, and minimum 
concentrations needed to inhibit growth for various bacterial species, while patenting the 
fermentation and production process (Finlay and Hobby, 1950). These compounds 
quickly obtained wonder-drug status, and, aside from their gram-positive and gram-
negative antibiotic effect, derivatives have had therapeutic indications to include the 
treatment of infectious diseases such as Chlamydiae, mycoplasmas, and rickettsiae, as 
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well as noninfectious diseases such as bone resorption, cartilage degradation, diabetes, 
periodontal disease, arthritis, and cancer (Chopra and Roberts, 2001; Greenwald and 
Golub, 2001). 
The tetracycline family of therapeutics is founded on the ABCD naphthacene 
ring-based chemical structure (Figure 1-9) and positional locants (locants are used to 
specify the position of a functional group within a molecule) designated at scaffold 
positions C1 (carbon number 1) through 12a (the carbon that is part of ring A and is also 
bound to C12). Nitrogen- and oxygen-containing functional groups are attached to C10, 
C11, C12, C1, as well as the 2N region and C3-C4 regions. Most medicinal derivatives of 
tetracycline have a pattern of hydroxyl, keto-enol, and carbonyl groups, attached at the 
lower peripheral region, owing to the molecule’s potency and selectivity. The functional 
groups across the lower peripheral region are critical for Mg2+-binding, and the bacterial 
ribosome contains a Mg2+ that guides the molecule into its binding position. Thus, some 
chemical changes to the lower peripheral region result in loss of antibacterial activity. 
The functional groups bound at the upper peripheral region (carbons 5 – 9) also dictate 
the derivative’s pharmacological characteristics. Chemical derivatization surrounding the 
D-ring aromatic region resulted in second- and third-generation tetracycline-based 
antibiotics. The exocyclic carbonyl attached to carbon 2 and the keto-enolate group 
bound to carbon 3 also mediates antimicrobial activity, and broad-spectrum effectiveness 
is based on the orientation of the C4 dimethylamino group.   
In E. coli, the mechanism of action for tetracyclines involves binding the 
ribosomal 30S subunit (Last, 1969; Chopra and Roberts, 2001) and excluding the 
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incoming aminoacyl-tRNA from the acceptor (A-site) site (Semenkov et al., 1982). 
However, tetracyclines also are known to chelate metal ions, as tetracyclines complexed 
with proteins containing divalent metal atoms are capable of inhibiting enzymatic activity 
of zinc- (or calcium-) containing enzymes, i.e., matrix metalloproteinase. Evidence has 
been marshaled supporting the theory that tetracyclines inhibit enzymes by binding: (1) 
catalytic and structural zinc atoms (Greenwald et al., 1998), (2) enzyme-associated zinc 
atoms in positions other than active sites (Smith et al., 1999), and (3) soluble zinc atoms 
before binding active sites as tetracycline — metal ion complexes (Takahashi et al., 
1991).  
 
Figure 1-9. The Tetracycline ABCD Ring System and Designation of the Upper and 
Lower Peripheral Regions. (Image courtesy of Mark Nelson) 
 
Objectives and Rationale for Study 
Most structural and mechanistic work on prokaryotic acetyl-CoA carboxylase has 
focused on biotin carboxylase. After the crystal structure of carboxyltransferase was 
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solved, a zinc finger, or putative nucleic-acid binding domain, was revealed (Bilder et. 
Al., 2006). Thus, our goal was to understand the function of this supersecondary 
structure.  
Our preliminary objective was to determine the nucleic-acid binding capacity of 
the enzyme. Next we wondered, “What is the ideal nucleic-acid substrate, and how is this 
related to regulation?” After we concluded that the enzyme bound DNA nonspecifically, 
high-affinity and specific binding to RNA was confirmed. Subsequently, we supposed the 
presence of biotin and acetyl-CoA, the reaction substrates, would have some effect on 
nucleic-acid binding. The next obvious question became, “Do nucleic acids inhibit 
carboxyltransferase-mediated catalysis?” After the inhibitory patterns were produced for 
nucleic acids and heparin, we studied the inhibitory effects of a class of molecules that 
was only recently found to inhibit the enzyme, namely the tetracyclines. At that point, we 
wanted to determine (a) the inhibition patterns and (b) if tetracyclines were sufficient to 
prevent nucleic-acid binding and then we wanted to propose a hypothesis as to the 
biological relevance of this inhibition in the context of polyketide synthesis.  Lastly, to 
better understand inhibitor binding sites and modes of action we wondered how each of 
these inhibitors might function in the presence of a second inhibitor. 
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CHAPTER 2 
LINKAGE BETWEEN NUCLEIC ACID BINDING AND CATALYSIS IN THE 
CARBOXYLTRANSFERASE SUBUNIT OF ACETYL-COA CARBOXYLASE* 
Introduction 
Carboxyltransferase is one component of the multifunctional biotin-dependent 
enzyme acetyl-CoA carboxylase, and the bacterial homolog of this enzyme contains a 
domain with no counterpart in the eukaryotic enzyme.  Acetyl-CoA carboxylase catalyzes 
the first committed and regulated step in fatty acid biosynthesis in bacteria via a two-step 
reaction (Scheme 1). 
 
Scheme 1 
In contrast to eukaryotes, which encode the multifunctional acetyl-CoA 
carboxylase as a single polypeptide chain, bacterial acetyl-CoA carboxylase is composed 
of three separate proteins: biotin carboxylase, carboxyltransferase, and biotin carboxyl 
carrier protein (BCCP) (Cronan and Waldrop, 2002).  Biotin is covalently attached to 
BCCP and this complex is designated Enzyme-biotin in Scheme 1.  Biotin carboxylase 
catalyzes the first half-reaction, which is an ATP-dependent carboxylation of biotin to 
form carboxybiotin.  The second half-reaction is catalyzed by carboxyltransferase, which 
transfers the carboxyl group from carboxybiotin to acetyl-CoA to generate malonyl-CoA.  
The recently obtained crystal structures (Figure 2-1) of carboxyltransferase from 
Escherichia coli and Staphylococcus aureus revealed a unique domain absent from  
* Reprinted by permission of The Journal of Protein Science                              
(1)  Enzyme-biotin  +  MgATP  +  HCO3
-
Mg2+
Enzyme-biotin-CO2
-  +  MgADP  +  Pi
(2)  Enzyme-biotin-CO2
-  +  Acetyl CoA Malonyl CoA  +  Enzyme-biotin
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eukaryotic homologs (Bilder et al., 2006).  The structure confirmed the α2β2 subunit 
composition suggested by Lane and colleagues (Guchhait et al., 1974) and showed that 
the enzyme belongs to the crotonase superfamily (Gerlt and Babbitt, 2001).  The overall 
fold, not surprisingly, is similar to that of carboxyltransferase from yeast (Zhang et al., 
2003) and Streptomyces coelicolor (Diacovich et al., 2004).  However, when the gene for 
the β subunit of E. coli carboxyltransferase was cloned and sequenced 20 years ago, the 
authors noted the tandem C-X-X-C sequences separated by 15 residues located at the 
amino terminus and hypothesized that the protein may bind a metal ion (Bognar et al., 
1987).  The crystal structures of carboxyltransferase from S. aureus and E. coli, along 
with X-ray fluorescence studies, have confirmed this prediction.  The metal atom is zinc, 
and it forms part of a zinc motif that is unique to bacterial carboxyltransferase (Figure 2-
1).  A space-filling representation reveals that the Zn domain forms part of a saddle-like 
structure (Figure 2-2), and an electrostatic surface potential rendering shows that the 
inner face of the zinc finger domain has an electropositive surface potential, while most 
of the protein has an electronegative surface potential. 
Given that Zn domains are commonly associated with nucleic acid binding, and 
noting the favorable electrostatic potential, we explored the ability of E. coli 
carboxyltransferase to bind nucleic acids.  Herein nucleic acid binding properties of E. 
coli carboxyltransferase are characterize along with the effect of DNA binding on 
enzymatic activity.  Notably, DNA exhibits synergism with a bisubstrate analog inhibitor 
and with heparin, suggesting communication between the dual active sites of the 
functional protomers. 
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Figure 2-1.  Ribbon Drawing of Carboxyltransferase from S. aureus.  The α-chain is in 
purple and the β-chain is in gold.  The zinc atom is depicted as a blue sphere in the β-
chain. 
 
Figure 2-2.  Electrostatic Surface Potentials of the Heterotetramer of Carboxyltransferase.  
Blue represents a net positive charge, while red represents a net negative charge.  The 
surface potentials were generated with the program Grasp (Nicholls et al., 1991). 
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The potential for the binding of DNA or structural analogs of DNA to affect 
enzymatic activity of carboxyltransferase is particularly significant because there is 
renewed interest in targeting enzymes in the bacterial fatty acid biosynthetic pathway for 
antibiotic drug discovery (Campbell and Cronan, 2001; Zhang et al., 2006).  Since the 
zinc finger domain is only found in the bacterial form of the enzyme, it provides a unique 
target to achieve specificity for pharmaceutical intervention. 
Materials and Methods  
Restriction enzymes, dNTPs, and T4 DNA ligase were purchased from New 
England Biolabs.  Pfu Turbo DNA polymerase was from Stratagene.  Primers for PCR 
and oligonucleotides used to generate dsDNA and ssDNA used as inhibitors were 
obtained from MWG BioTech.  Heparin was from Sigma/Aldrich.  The bisubstrate 
analog (BiSA) inhibitor of carboxyltransferase was synthesized according to the method 
of Levert and Waldrop (17)  [γ-32P] ATP and [α-32P] UTP were from PerkinElmer, and 
MegaScript/ MegaClear/ RNase Zap was acquired from Ambion, Inc.  QIAquick Gel 
Extraction Kit and DNeasy Tissue Kit were from Qiagen, Inc.  IHF was obtained as 
described by Grove et al. (Grove et al., 1996), MfpA was kindly provided by Dr. John 
Blanchard, Albert Einstein College of Medicine.   
Purification and Enzymatic Assay of Carboxyltransferase  
Carboxyltransferase was purified from E. coli transformed with an overexpression 
plasmid containing a mini-operon with genes for the α and β subunits of the enzyme 
(Blanchard and Waldrop, 1998).  Carboxyltransferase activity was measured in the 
reverse direction with a spectrophotometric assay in which the production of acetyl-CoA 
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was coupled to the combined citrate synthase- malate dehydrogenase reaction requiring 
NAD+ reduction. Biocytin is preferred over biotin because biocytin produces a maximal 
velocity three orders of magnitude greater than does biotin.45 Biocytin is a biotin 
molecule with a lysine appended to the carboxyl group of the valeric acid side chain via 
an amide linkage at the ε-amino group (Blanchard and Waldrop, 1998).  NADH 
formation was followed spectrophotometrically at 340 nm using a Uvikon 810 (Kontron 
Instruments) spectrophotometer interfaced to a PC equipped with a non-commercial data 
acquisition program.  Since the crystal structure showed that carboxyltransferase contains 
two active sites, the initial velocities were calculated per active site using a molecular 
weight of 68.5 kDa for each αβ dimer (i.e., active site).  Control experiments showed that 
neither DNA nor heparin at the highest concentration inhibited the coupling enzymes 
citrate synthase or malate dehydrogenase.  
Substrate Nucleic Acids  
The promoter regions for the α (292 bp and 500 bp fragments) and β (175 bp and 
300 bp fragments) genes of carboxyltransferase, the promoter region for the biotin 
carboxylase/ biotin carboxyl carrier protein (300 bp fragment) and a 280 bp control 
fragment encompassing part of the accD coding region were PCR amplified using the 
primers listed in Table 2-1.  E. coli (JM109, New England Biolabs) chromosomal DNA 
isolated via DNeasy Tissue kit was used as the template.  The PCR products were 
electrophoresed and their concentration was assessed by densitometry by comparing 
sample intensity to that of similar sized molecular weight standards.  The PCR products 
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were 5′-end labeled with T4 polynucleotide kinase and [γ-32P] ATP and purified via 
QIAquick Gel Extraction Kit, assuming 90% sample recovery.   
The mRNA encoded by the genes for α (accA) and β (accD) subunits of 
carboxyltransferase, including their respective leader sequences, was obtained as follows.  
The accA gene (1190 bp) was PCR amplified from the E. coli genome using primers 
listed in Table 2-1.  Primers introduced EcoRI and BamHI sites at either end of the PCR 
product.  For the β subunit (accD, 1027 bp) an XhoI site was added to the 5′ end and a 
BamHI site was incorporated at the 3′ end.  These PCR products were cloned into pGEM-
11Zf(+).  The presence of both genes was confirmed via sequential digestions, agarose 
gel electrophoresis, and observation of the correct insert size.  These recombinant 
plasmids were linearized with BamHI and 390 ng of DNA was used as templates for in 
vitro transcription of accA and accD.  Two identical reactions were carried out except for 
the addition of 1µL of [α-32P] UTP to one reaction.  In vitro transcription and mRNA 
purification were carried out according to the instructions in MegaScript and MegaClear, 
respectively.  A 1.0% agarose gel was used to visualize the nonradioactive mRNA to 
confirm the correct size of the transcript.  The nonradioactive RNA was quantified by 
measuring its absorbance at 260 nm.  Measured parameters for the nonradioactive 
samples were applied to the radioactive samples.   
Eletrophoretic Mobility Shift Assay (EMSA) 
The reactions (total reaction volume of 10 µL) included 50 fmol of DNA or RNA, 
with carboxyltransferase titrated from 0 to 2.6 µM for assays involving DNA and 0 to 0.6 
µM for assays involving RNA.  The binding buffer was: 20 mM Tris-HCl (pH 8), 0.1 
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mM Na2EDTA, 0.075% BRIJ58, 50 mM NaCl, 5 mM MgCl2, 50 µg/ml BSA, and 4% 
(v/v) glycerol.  Reactions were incubated on ice for 0.5 h. Samples were resolved on 
prerun 6.0% (w/v) native polyacrylamide gels (39:1 acrylamide:bisacrylamide) at room 
temperature in TBE buffer (45 mM Tris borate (pH 8.3), 1.25 mM Na2EDTA), and 
samples were loaded with the power on.  After 2.0 h of electrophoresis, the gels were 
dried and complexes were visualized by phosphorimaging and quantified using 
ImageQuant TL (GE Healthcare).  For calculating percent complex formation, the region 
on the gel from the slowest migrating complex to the free nucleic acid was considered as 
complex.  Percent complex was calculated as complex intensity divided by the total 
intensity (or total nucleic acid) in a given lane.  Binding assays were carried out in 
duplicate.  Binding isotherms are from representative EMSAs, with less than 17.5% 
variation between experiments. 
Inhibitors of DNA and RNA binding by carboxyltransferase were analyzed by measuring 
percent complex versus inhibitor concentration.  A competition assay was carried out 
similar to the binding assay for affinity determination (above), except the 
carboxyltransferase was held constant and the inhibitor concentration was varied. The 
order of addition for each of the regents in the competition assay is as follows: buffer, 
carboxyltransferase, inhibitor molecule(s), and labeled DNA.  
Data Analysis 
The binding isotherms for carboxyltransferase binding to DNA were analyzed by fitting 
the data to equation 1 to calculate the concentration of protein resulting in half-maximal 
saturation (EC50).   
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Table 2-1. Primers Used for Amplification of Substrate DNA or for Enzyme Inhibition 
Assays 
Primer  
Name 
Amplicon locus Upstream Primer  
Sequence (5′ to 3′) 
Downstream Primer  
Sequence (5′ to 3′) or  
complement for annealing 
accD #1 -161 to +13 AAATAAAAAGTAACT
CCGCGGTTCG 
TCAATCCAGCTCATTAGGG
ACCTTT 
accD #2 -288 to +11 TTTCTTCGGTACAATC
CCGATGGT 
AATCCAGCTCATTAGGGAC
CTTTC  
accA #1 -6,729 to -6,437 CAAAGTCTGGCGCAA
AACCGCTGC 
CTTCAAAATCCAGCACGCG
ATCCA 
accA #2 -495 to +4 GTTGCCGCGCGGGTTA
TGGTCACC 
CTCATAGTATTCCTGTATT
AGTCA  
 
accB/C -292 to +7 TTGCTACGAAATCGTT
ATAATGTG 
ATATCCATGAGTGGGTTCC
GTACT  
control -28 to +251 GCCTGGCATTTGCTGA
ATTTGACGA 
TCGTCAAATTCAGCAAATG
CCAGGC 
ivt 
accA 
-213 to +960  GCCGGGAATTCTGACC
AGCTTTTAAACCG 
CCGGCGGATCCTTACGCGT
AACCGTAGCTC 
ivt 
accD 
-96 to +914 
 
GCCGGCTCGAGTGTGC
AACATTCATGGTCT 
CCGGCGGATCCTCAGGCCT
CAGGTTCCTGA 
4 nt N/A TACG N/A 
30 nt N/A TGACCATGATTACGCC
AAGCTATTTAGGTG 
CACCTAAATAGCTTGGCGT
AATCATGGTCA 
    
Amplicon locus is given relative to the A of the start codon (ATG).  Primers accD 
#1 and #2 were used to amplify a 175 bp and a 300 bp region of the E. coli chromosome 
predicted to contain the promoter for accD (carboxyltransferase β gene).  accA #1 and #2 
were used to amplify a 292 bp and a 500 bp region of the E. coli chromosome predicted 
to contain the promoter for accA (carboxyltransferase α gene).  accB/C were used to 
amplify a 300 bp region of the E. coli chromosome reported to contain the promoter for 
the accB and accC (genes for biotin carboxylase and biotin carboxyl carrier protein, 
respectively).  “Control” was used to amplify a 280 bp region starting at the 5′ end of the 
coding sequence within accD.  ivt accA was used to amplify accA from the -213 position 
(Li and Cronan, 1993) to the end of the gene to generate template for in vitro 
transcription.  ivt accD was used to amplify accD from the -96 position (Li and Cronan, 
1993) to the end of the gene and was used to generate in vitro transcription template.  The 
4 nt and both 30 nt were used to study the inhibitory affects of DNA on catalysis by 
carboxyltransferase.  
 
 73 
 
 
 
In equation 1, Y equals the fractional complex, while min is the minimum value 
of Y and max is the maximum value of Y. “x” is the concentration of carboxyltransferase 
and n is the Hill coefficient.  The binding isotherms for carboxyltransferase binding to 
RNA were analyzed by fitting the data to equation 2 where Kd reflects half maximized 
saturation, Y is the fractional complex, X is concentration of carboxyltransferase, and 
Ymax is the maximal complex or horizontal asymptote. 
Competitive inhibition data were fitted to equation 3, using the programs of 
Cleland (Cleland, 1979).  In equation 3, v is the initial velocity, Vm is the maximal 
velocity, A is the substrate concentration, I is the concentration of inhibitor, Km is the 
Michaelis constant, Kis is the slope inhibition constant.  Data for multiple inhibition were 
fitted to equation 4 where v is the initial velocity, I and J are the concentrations of the two 
inhibitors, v0 is the velocity in the absence of inhibitors, Ki and Kj are the apparent 
dissociation constants for the two inhibitors and β is a measure of the degree of 
interaction of the two inhibitors (Cleland, 1990). 
 Y = min+ !"!!!"#!!!" !"#$%&'!! ∗!     [1] Y = !!"#!!!!  !        [2] v = !!∗!!! !! !!!" !!      [3] v = !!!! !!!! !!!! !"!!!!!      [4] 
 
Results 
DNA Binding by Carboxyltransferase 
 74 
 
 
 
To address the functional significance of the unique Zn domain, we first pursued 
its potential role in DNA binding.  Since the four components (i.e. biotin carboxylase, 
BCCP and the α and β subunits of carboxyltransferase) of the E. coli acetyl-CoA 
carboxylase are likely produced in a defined, stoichiometric ratio, and since expression of 
the genes has been reported to be directly correlated to cellular growth rates (Li and 
Cronan, 1993), we explored the possibility that carboxyltransferase may contribute to 
regulation of any of the genes encoding the acetyl-CoA carboxylase subunits.  
The gene encoding the Zn domain-containing β subunit (accD) is located between 
the dedA (Nonet et al., 1987) and the folC (Bognar et al., 1987) genes.  Li and Cronan (Li 
and Cronan, 1993) suggested that accD is transcribed monocistronically and that the 
accD mRNA starts 87 bp upstream of the coding region.  The ability of 
carboxyltransferase to bind a 175 bp DNA containing the 5′ noncoding region of accD 
was tested using electrophoretic mobility shift assay (EMSA).  As shown in Figure 2-3A, 
carboxyltransferase binds DNA as evidenced by the formation of a complex that fails to 
migrate from the well of the gel (designated as complex 1).  The complex (designated 
complex 2) that migrates much faster than complex 1 may represent a very compact 
species, perhaps resulting from a single DNA molecule wrapping around the enzyme 
molecule, which contains two zinc domains located on opposite lobes.  Quantification of 
the data shows that DNA binds to carboxyltransferase in a cooperative fashion (Figure 2-
3B), with nH = 1.7 and a half-maximal saturation of 946 ± 32 nM (Table 2-2).  Half-
maximal saturation of 300 bp DNA that included the 3′ end of the dedA gene was similar 
to that measured for the 175 bp fragment (Table 2-2).     
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Table 2-2. Half-Maximal Values for Carboxyltransferase Binding to Substrate DNA 
Molecules 
DNA EC50 (nM) Hill Slope 
175 bp carboxyltransferase β promoter 946 (+/- 32) 1.7 (+/- 0.2) 
300 bp carboxyltransferase β promoter 673 (+/- 36) 1.8 (+/- 0.2) 
292 bp carboxyltransferase α promoter 751 (+/- 25) 2.1 (+/- 0.2) 
500 bp carboxyltransferase α promoter  821 (+/- 28) 2.0 (+/- 0.2) 
300 bp BCCP/ BC promoter 794 (+/- 47) 1.5 (+/- 0.2) 
280 bp control sequence 783 (+/- 37) 1.5 (+/- 0.2) 
30 nt PCR primer  480 (+/- 18) 2.6 (+/- 0.2) 
EC50 values and Hill slope for DNA substrates were determined by quantifying EMSA gels 
and fitting data to equation 1. 
 
 
 
Figure 2-3.  Electrophoretic Analysis of 175 bp dsDNA from Promoter Region of accD 
(carboxyltransferase β subunit) titrated with carboxyltransferase.  A, reactions contain 
50.0 fmol DNA.  Reactions in lanes 2 - 14 contain: 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 1.4, 
1.6, 1.8, 2.0, 2.2, 2.4, and 2.6 µM carboxyltransferase.  B, binding isotherm for 
carboxyltransferase binding to 175 bp dsDNA. 
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(Figure 2-3 continued) 
 
 
 
 
 
The gene coding for the α subunit (accA) of carboxyltransferase is located 
downstream of the polC gene (Li and Cronan, 1992), and Li and Cronan (Li and Cronan, 
1993) suggested that the promoter is located within the 3′ end of the polC coding 
sequence.  Carboxyltransferase bound to 292 and 500 bp DNA fragments encompassing 
the promoter region of accA (data not shown).  As with the promoter region for the β 
subunit, binding was cooperative and the half-maximal saturation was between 0.5 and 
1.0 µM (Table 2-2).  Similarly, low-affinity binding of carboxyltransferase to a 280 bp 
DNA representing the accD coding region and to a 300 bp DNA containing the promoter 
region for the operon that includes the genes for biotin carboxylase and the biotin 
carboxyl carrier protein was observed (Table 2-2), and the binding was cooperative.   
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The comparable half-maximal saturation of the DNA sequences examined 
suggests that carboxyltransferase binds DNA nonspecifically.  To confirm nonspecific 
DNA binding, a competition assay was performed.  The addition of unlabeled 175 bp β 
subunit promoter DNA fails to inhibit complex formation with the labeled DNA, even at 
a 10-fold molar excess of unlabeled competitor (Figure 2-4).  The increase in complex 
formation in the presence of higher amounts of unlabeled 175 bp β subunit promoter 
DNA is likely attributable to a carboxyltransferase concentration below the Kd for single 
site binding.  A titration of the cloning vector pGEM5 (up to a 10-fold molar excess) 
reveals inhibition of the carboxyltransferase DNA complex, further confirming 
nonspecific binding (Figure 2-4).  Inhibition was independent of DNA conformation 
(supercoiled or linear, data not shown). 
So far, the data indicate that carboxyltransferase binds duplex DNA 
nonspecifically and with low affinity.  While it cannot rule out that carboxyltransferase 
may be recruited to specific DNA sites by association with other factors, it is noted that 
addition of biotin carboxylase or the biotin carboxyl carrier protein (biotinylated and 
unbiotinylated) did not increase the affinity of carboxyltransferase for duplex or single-
stranded DNA, suggesting that the other components of acetyl-CoA carboxylase do not 
confer high affinity DNA binding (not shown).  Considering the potential for 
carboxyltransferase looping DNA and the presence of AT-rich sequences weakly 
resembling consensus binding sites for integration host factor (IHF) (Freundlich et al., 
1992; Hales et al., 1994; and Hales et al., 1996), we assessed the ability of IHF to 
enhance carboxyltransferase-DNA complex formation.  IHF did not increase the affinity 
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of carboxyltransferase for either of the promoter regions of the genes for the α and β 
subunits (data not shown).     
 
Figure 2-4.  DNA Competition Assay.  Reactions contain 50 fmol labeled 175 bp 
carboxyltransferase β promoter, reactions in lanes 2 - 15 have 600.0 nM 
carboxyltransferase.  Unlabeled 175 bp carboxyltransferase β promoter DNA (lanes 3 - 8) 
and pGEM5 (lanes 10 – 15) are titrated using molar ratios of unlabeled DNA/ labeled 
DNA from 0.2 to 10 (3.4 – 171 molar ratio of bp for pGEM5). 
 
Carboxyltransferase binds ssDNA in preference to duplex (Figure 2-5, A).  
Although the EC50 for ssDNA was not significantly lower than the EC50 for  the 30 nt 
dsDNA (Figure 2-5, B, Table 2-2), the ssDNA has orders of magnitude fewer binding 
sites in comparison to other dsDNA tested, suggesting a lower Kd for each single site.  As 
seen for binding to duplex DNA, carboxyltransferase binds ssDNA cooperatively.  In 
light of this result DNA mimetics were tested for their ability to bind to 
carboxyltransferase.  Not surprisingly, the DNA mimic heparin did inhibit formation of 
the carboxyltransferase-DNA complex (data not shown).  In contrast, MfpA, a protein 
from Mycobacterium tuberculosis that provides resistance to fluoroquinolones by 
mimicking DNA and binding to DNA gyrase (Hedge et al., 2005) did not inhibit 
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formation of the carboxyltransferase-DNA complex (not shown).  Taken together, the 
results indicate that carboxyltransferase binds DNA nonspecifically and with low affinity. 
 
 
 
 
 
 
Figure 2-5.  Electrophoretic Analysis of 30 nt ssDNA Versus 30 bp dsDNA Titrated with 
Carboxyltransferase.  A, Lane 1 is ssDNA (50.0 fmol).  The remaining reactions 
contained a 50 fmol ssDNA with one-half molar ratio complementary strand, annealed by 
cooling from 95°C to 0°C over 3 hours.  Reactions in lanes 3 - 14 contain increasing 
amounts of carboxyltransferase (from 0.1 to 2.4 µM).  B, binding isotherm for 
carboxyltransferase binding to ssDNA (30 nt upstream primer sequence, Table 2-1). 
  
 80 
 
 
 
 
 
 
 
Figure 2-6.  A, Competition Assay with RNA.  All reactions have 50.0 fmol 280 bp 
labeled DNA (control, Table 2-1) and 1.6 µM carboxyltransferase, except the reaction in 
lane 1 which has only free DNA.  The transcript from the gene for the α-subunit of 
carboxyltransferase is titrated in reactions in lanes 2 - 7.  The transcript from the gene for 
the β-subunit of carboxyltransferase is titrated between lanes 8 - 13.  The reaction in lane 
14 is labeled DNA and carboxyltransferase only.  Total RNA is titrated over the reactions 
in lanes 15 - 20.  tRNA from Saccharomyces cerevisiae is titrated over the reactions in 
lanes 21 - 26.  The titration for each type of RNA had mass ratios (DNA/ RNA) of 0.05, 
0.5, 1.0, 5.0, 50.0, and 500.0.  B, graphical representation of RNA competition EMSA. 
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Figure 2-7.  Electrophoretic Analysis of the Transcript from Carboxyltransferase α 
Subunit Titrated with Carboxyltransferase.  A, All lanes contain 50.0 fmol mRNA, while 
lanes 2 - 14 contain 1.0, 5.0, 10.0, 25.0, 40.0, 55.0, 70.0, 85.0, 100.0, 200.0, 300.0, 400.0, 
500.0, and 600.0 nM carboxyltransferase.  B, binding isotherm for carboxyltransferase 
binding to the transcript from carboxyltransferase α subunit. 
 
RNA Binding by Carboxyltransferase 
Considering that the closest structural homolog of the carboxyltransferase Zn 
domain is from the 50S ribosomal protein L37Ae (Bilder et al., 2006), the ability of 
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carboxyltransferase to bind RNA was investigated.  Four different types of RNA were 
tested for their ability to inhibit formation of the DNA:carboxyltransferase complex.  The 
RNA molecules considered included mRNA coding for the α subunit, mRNA coding for 
the β subunit, a total RNA extract from E. coli, and a tRNA extract from Saccharomyces 
cerevisiae.  All four types of RNA were found to inhibit formation of the 
carboxytransferase-DNA complex (Figure 2-6A) indicating that carboxyltransferase also 
binds RNA.  Quantification of the data showed that the α subunit mRNA inhibited 
complex formation most effectively (Figure 2-6B).  Therefore, a transcript including the 
α subunit mRNA starting 213 nt upstream of the AUG (Li and Cronan, 1993) through the 
end of the structural gene was used in an EMSA (Figures 2-7A and B).  In contrast to the 
sigmoidal binding isotherm obtained for carboxyltransferase binding to DNA, fits of 
carboxyltransferase-RNA complex formation yield a hyperbolic curve with Kd, of 187 ± 
17 nM, which is about 3-5 fold lower than the half-maximal saturation for DNA binding.    
Inhibition of Enzyme Activity  
While the EMSA studies indicated that carboxyltransferase binds nucleic acids 
nonspecifically and with low affinity, the important question was whether DNA binding 
had any impact on the enzymatic function of carboxyltransferase.  As shown in Figure  
2-8, increasing concentrations of a 4 nt, 30 nt and 30 bp fragment of DNA did indeed 
result in a decrease in enzymatic activity.  It was not possible to test larger DNA 
fragments because the increased viscosity of the assay solution became prohibitive.  A 
single stranded DNA substrate (30 nt upstream sequence, Table 2-1) was used to examine 
the type of inhibition with respect to the substrates malonyl-CoA and biocytin†.  The 30 
 83 
 
 
 
nt ssDNA exhibited competitive inhibition with respect to both malonyl-CoA and 
biocytin (Figure 2-9A and B).  Fitting the data to equation 3 gave slope inhibition 
constants (Kis) of 85.1 ± 10.3 µM, with respect to malonyl-CoA and 34.2 ± 4.0 µM, with 
respect to biocytin.  Heparin was also found to inhibit enzymatic activity, and like DNA, 
exhibited competitive inhibition with respect to both substrates (Figure 2-9C and D).  The 
slope inhibition constants (Kis) for inhibition by heparin are 1.2 ± 0.1 µM with respect to 
malonyl-CoA, and 2.2 ± 0.3 µM with respect to biocytin.  
 
Figure 2-8.  Dose Response Curve for Carboxyltransferase with Both ssDNA and 
dsDNA.  Initial velocity was measured at increasing amounts of DNA (4 nt ssDNA, 30 nt 
ssDNA, and 30 nt dsDNA, Table 2-1). 
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Figure 2-9.  Inhibition of Carboxyltransferase by DNA (A and B) and Heparin (C and D).  
When malonyl-CoA was the variable substrate, biocytin was held constant at 5.0 mM, 
and when biocytin was the variable substrate, malonyl-CoA was held constant at 0.1 mM.  
The points are the reciprocal of the experimental velocities and the lines are derived from 
the best fit of the data to equation 3. 
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(Figure 2.9 continued) 
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Figure 2-10.  Inhibition of the Formation of DNA: Carboxyltransferase Complex by 
Substrates and Substrate Analog.  All reactions contained 50 fmol 300 bp 
carboxyltransferase β promoter DNA.  A, reactions in lanes 2 - 10 have 800.0 nM 
carboxyltransferase, malonyl-CoA is titrated in reactions from lanes 3 - 10 (from 10.0 µM 
to 10.0 mM).  B, reactions in lanes 2 - 8 have 800.0 nM carboxyltransferase, biocytin is 
titrated in reactions in lanes 3 - 8 (from 800.0 µM to 800.0 mM).  C, reactions in lanes 2 - 
10 have 800.0 nM carboxyltransferase, BISA is titrated in reactions in lanes 3 - 10 (from 
2.5 µM to 2.5 mM). 
 
 
 
resembling consensus binding sites for integration host
factor (IHF) (Freundlich et al. 1992; Hales et al. 1994,
1996), we assessed the ability of IHF to enhance carboxyl-
transferase–DNA complex formation. IHF did not increase
the affinity of carboxyltransferase for either of the promoter
regions of the genes for the a- and b-subunits (data not
shown). Taken together, the results indicate that carboxyl-
transferase exhibits nonspecific, cooperative DNA binding.
Discussion
DNA-binding enzymes
Few enzymes that catalyze a reaction in intermediary
metabolism also bind DNA or RNA. Examples include PutA
(proline utilization A) (Brown and Wood 1992); BirA or
biotin ligase, which attaches biotin to the biotin carboxyl
carrier protein (Beckett 2005); the plant cysteine protease
LeCp (Matarasso et al. 2005); Arg 5,6, which is involved
in arginine biosynthesis (Hall et al. 2004); Ilv5p, which
catalyzes a reaction in branched-chain amino acid biosyn-
thesis (Bateman et al. 2002a); and iron regulatory protein 1
(IRP1), which binds mRNA and functions as aconitase
(Walden et al. 2006). These proteins all have dual functions;
they either act as enzymes or as nucleic acid binding
proteins, and, most importantly, these two functions can be
separated. For example, the DNA-binding domain of PutA
Figure 4. Inhibition of carboxyltransferase by (A, B) DNA and (C, D)
heparin. When malonyl-CoA was the variable substrate, biocytin was held
constant at 5.0 mM, and when biocytin was the variable substrate,
malonyl-CoA was held constant at 0.1 mM. The points are the reciprocal
of the experimental velocities, and the lines are derived from the best fit of
the data to Equation 1. The error on each velocity is <10%.
Figure 5. Inhibition of the formation of DNA:carboxyltransferase com-
plex by malonyl-CoA and BiSA. All reactions contained 50 fmol of 300-bp
carboxyltransferase b promoter DNA. (A) Reactions in lanes 2–10 have
800.0 nM carboxyltransferase; malonyl-CoA is titrated in reactions from
lanes 3–10 (from 10.0 mM to 10.0 mM). (B) Reactions in lanes 2–10 have
800.0 nM carboxyltransferase; BISA is titrated in reactions in lanes 3–10
(from 2.5 mM to 2.5 mM).
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These inhibition data are consistent with EMSA assays, which show that 
increasing concentrations of either malonyl-CoA or biocytin inhibit formation of the 
carboxyltransferase-DNA complex (Figure 2-10A and B).  Moreover, a bisubstrate 
analog (BiSA) inhibitor of carboxyltransferase, in which coenzyme A is covalently 
attached to carboxybiotin (Levert and Waldrop, 2002) was an even more efficient 
inhibitor of the enzyme-DNA complex (Figure 2-10C). 
The competitive inhibition patterns observed for DNA and heparin versus the 
substrates malonyl-CoA and biocytin suggest that DNA and heparin bind in the active 
site of carboxyltransferase.  However, this seemed curious given the significant 
difference in structure between the substrates and the fact that DNA and heparin are 
polymers.  Therefore, to characterize the topological relationship between the DNA 
binding site and the active site (e.g., do the two sites overlap) multiple inhibition studies 
were performed.  Multiple inhibition experiments are carried out by measuring the initial 
velocity at increasing concentrations of one inhibitor while the second inhibitor is held 
constant.  The substrate concentrations are held constant at subsaturating levels.  The 
initial velocities are measured again at higher levels of the second inhibitor and then 
plotted as 1/velocity versus the concentration of the first inhibitor (sometimes referred to 
as a Yonetani-Theorell plot) (Yonetani and Theorell, 1964).  The first inhibitor for these 
studies was the bisubstrate analog (BiSA) used above for the EMSA assays.  It is 
important to note that the substrate concentrations are held constant at subsaturating 
levels for multiple inhibition analyses, which enables BiSA to bind to the enzyme.   
Double inhibition of carboxyltransferase by either DNA or heparin at different 
fixed levels of BiSA (Figure 2-11A and B) yielded intersecting patterns, which indicate 
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that the two inhibitors can bind to the enzyme simultaneously.  Thus, the binding site for 
DNA and the active site of the enzyme are topologically distinct, which suggests DNA 
binding at one αβ dimer while BiSA binds to the other αβ dimer.  This scenario is 
supported by fitting the data to equation 4; β values of 0.50 and 0.85 were found for the 
DNA-BiSA inhibition and the heparin-BiSA inhibition, respectively.  The β value is an 
indication of the interaction of the two inhibitors.  Values of β greater than 1 indicate that 
the binding of the two inhibitors interfere with one another, while a value of 1 indicates 
no interaction between the inhibitors.  A β value less than 1 indicates synergism in the 
binding of the inhibitors.  Thus, the binding of either DNA or heparin shows very weak 
synergism with the binding of BiSA and vice versa.  Surprisingly, double inhibition 
analysis with DNA and heparin also resulted in an intersecting pattern (Figure 2-11C), 
indicating that DNA and heparin can bind to the enzyme simultaneously.  However, the β 
value of 0.02 reflects a strong synergistic relationship in the binding of the two inhibitors.  
Given the presence of two Zn domains per protomer, the simplest explanation is that 
binding at one site enhances binding at the other. 
Discussion 
DNA Binding Enzymes  
Few enzymes that catalyze a reaction in intermediary metabolism also bind DNA 
or RNA.  Examples include PutA (proline utilization A) (Brown and Wood, 1992); BirA, 
or biotin ligase, which attaches biotin to the biotin carboxyl carrier protein (Beckett, 
2005); the plant cysteine protease LeCp (Matarasso et al., 2005); Arg 5,6, which is 
involved in arginine biosynthesis (Hall et al., 2004); Ilv5p, which catalyzes a reaction in  
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Figure 2-11.  (A-C)  Multiple Inhibition Patterns for DNA (ssDNA 30 nt upstream 
sequence, Table 2-1), Heparin and BiSA.  The points are the reciprocal of the 
experimental velocities and the lines are derived from the best fit of the data to equation 
4.  Malonyl-CoA was held constant at 0.1 mM, while biocytin was held constant at 5.0 
mM. 
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(Figure 2-11 continued) 
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branched-chain amino acid biosynthesis (Bateman et al., 2002a); and iron regulatory 
protein 1 (IRP1), which binds mRNA and functions as aconitase (Walden et al., 2006).  
These proteins all have dual functions; they either act as enzymes or as nucleic acid 
binding proteins and, most importantly, these two functions can be separated.  For 
example, the DNA binding domain of PutA can be expressed and purified without the 
enzymatic domain, and it still binds DNA (Gu et al., 2004).  For Ilv5p, either the DNA 
binding domain or the enzymatic domain can be inactivated without affecting the activity 
of the other domain (Bateman et al., 2002b).  In contrast, the enzymatic activity and 
nucleic acid binding of carboxyltransferase are inextricably linked. 
Zinc Domains Associated with Proteins Involved in DNA Metabolism 
The zinc domain in bacterial carboxyltransferase belongs to the zinc ribbon class 
of zinc fingers (Krishna et al., 2003).  Other proteins that contain this type of zinc finger 
include the transcription factors TFIIS (Qian et al., 1993) TFIIB (Zhu et al., 1996) TFIIE 
(Okuda et al., 2004) several subunits from RNA polymerase II (Cramer et al., 2003) 
human ssDNA binding protein RPA (Cochkareva et al., 2002) bacteriophage T4 and T7 
primases (Cha and Alberts, 1986; Mendelman and Richardson, 1991) and several 
ribosomal proteins, most notably, L37E from the 50S subunit (PDB code 1JJ2).   
Carboxyltransferase was found to bind DNA non-specifically and with low 
affinity.  Compared to other proteins featuring the zinc ribbon motif, non-specific DNA 
binding by carboxyltransferase is not unexpected.  Isolated zinc fingers like that in 
carboxyltransferase do not bind DNA tightly and recognize only 3 nucleotides (Wolfe et 
al., 2000).  For example, T7 and T4 primases, which contain a zinc ribbon type of zinc 
 92 
 
 
 
finger, recognize a 3 nt sequence (Mendelman et al., 1999).  Recognition of 3 nt is 
consistent with the observation that enzymatic activity was inhibited as efficiently by a 4 
nt DNA as well as longer DNA molecules.  That carboxyltransferase also binds ssDNA 
and RNA is consistent with properties of other zinc ribbon proteins.  Clearly, zinc ribbons 
are associated with proteins involved in DNA metabolism, even if some, such as the 
domain found in TFIIB mediates interactions with the large RNA polymerase subunit and 
not nucleic acid, however, this zinc ribbon is almost entirely β-sheet and has less in 
common with other characterized zinc ribbons.  While we have not found evidence for a 
role in regulation of gene expression, we cannot rule out the possibility that 
carboxyltransferase may be recruited to specific sites.  Could the non-specific DNA 
binding by carboxyltransferase be an evolutionary relic?  We consider this interpretation 
unlikely, given the close mechanistic relationship between DNA binding and catalysis.  
Does Carboxyltransferase Bind DNA in Vivo? 
A prediction as to whether carboxyltransferase binds DNA in vivo can be made by 
assuming a 3 nt binding site which is consistent with other zinc finger binding sites 
(Wolfe et al., 2000) and with inhibition of enzymatic activity by 4 nt DNA.  However, 
based on the dimensions of carboxyltransferase a single molecule of enzyme would 
occlude approximately 30 bp.  Given that the concentration of the E. coli genome is 5 nM 
(Sundararaj et al., 2004) and with 4.6 x 106 bp in the E. coli genome (Mathews et al., 
1999) there would be 1.5 x 105 or 0.75 mM potential binding sites for 
carboxyltransferase.  The intracellular concentration of carboxyltransferase is 
approximately 500 nM (Guchhait et al., 1974).  Using 0.8 µM as the binding constant of 
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DNA to carboxyltransferase, the fraction of carboxyltransferase bound to DNA 
intracellularly can be calculated with the following equation (Segel, 1975): 
[ES] = (1/2) (([Et] + [St] + Ks) - (([Et] + [St] + Ks)2 - 4[Et] [St])½) 
where Et is the concentration of carboxyltransferase, St is the concentration of DNA 
binding sites and Ks is the dissociation constant for DNA binding to carboxyltransferase.  
Assuming that the entire E. coli genome is accessible to carboxyltransferase, the 
calculation suggests that all of the enzyme would be bound to DNA in vivo.  However, 
most of the genomic DNA in E. coli is compacted by proteins (Minsky, 2004) and would 
be inaccessible to carboxyltransferase, yet recalculation assuming only 10% of the 
genomic DNA available for binding to carboxyltransferase also suggests that all of the 
carboxyltransferase in E. coli would be bound to DNA.  The levels of RNA in E. coli 
were not included in this calculation, but if they were, it would only reinforce the 
conclusion that all of the carboxyltransferase is bound to either DNA or RNA in the cell. 
What might be the consequences of a significant fraction of carboxyltransferase 
being bound to nucleic acids?  The observation that both substrates inhibit DNA binding 
is very important when considering how carboxyltransferase could function as a critical 
enzyme for membrane biogenesis.  It is tempting to speculate that during the stationary 
phase of E. coli growth where nutrients are limited, carboxyltransferase functions as a 
nucleoid-associated protein (Drlica and Rouviere, 1987) to compact and protect the 
chromosome from damage. During the growth phase when nutrients are abundant, the 
levels of substrates, most notably acetyl-CoA, increase dramatically and compete with 
DNA for binding to carboxyltansferase and the enzyme functions to synthesize fatty acids 
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for cell membrane assembly.  During stationary phase, when carboxyltransferase activity 
is low, association with nucleic acids may also prevent futile activity and/or the 
sequestration of cellular metabolites.   
The Mode of DNA Binding Suggests Communication Between the Dual Active Sites 
DNA and heparin are competitive inhibitors with respect to both substrates 
malonyl-CoA and biocytin.  The competitive inhibition patterns indicate that saturating 
levels of either substrate prevent DNA binding.  This makes intuitive sense for malonyl-
CoA; the β subunit contains the zinc domain, the presumed DNA binding site, in close 
proximity to the malonyl-CoA binding site.  Biocytin, however, binds to the α subunit.  
The competitive inhibition pattern could be due to a steric effect where the polymeric 
DNA blocks access to the biocytin binding site.  Alternatively, biocytin binding to the α 
subunit could propagate a conformational change to the β subunit to inhibit DNA 
binding.  Inhibition of carboxyltransferase by DNA is consistent with EMSA data 
showing that both malonyl-CoA and biocytin as well as a bisubstrate analog prevent 
formation of the DNA-protein complex.  Thus, enzymatic activity and DNA binding are 
not separable functions. 
The cooperative binding of DNA to carboxyltransferase is likely a possible 
manifestation of two separate physical phenomena.  Carboxyltransferase has two zinc 
domains diametrically opposed and DNA has multiple binding sites.  Accretion of 
carboxyltransferase mediated by protein-protein interactions could account for the 
observed cooperativity.  Assuming protein-protein interaction as the driving force, 
however, it is difficult to imagine why such recruitment would not occur on RNA, to 
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which carboxyltransferase does not bind cooperatively.  Second, the binding of DNA to 
one site on carboxyltransferase could increase the affinity for DNA binding to the second 
site.  Evidence for intersubunit communication is also seen in the multiple inhibition 
experiments with DNA and heparin (Figure 2-11) where the β value, which reports on the 
degree of synergism in the binding of the two inhibitors, is well below 1 (0.02).  This 
synergistic binding of DNA to carboxyltransferase could certainly contribute to the 
sigmoidal curve observed in Figure 2-3B.  While DNA binding to carboxyltransferase is 
clearly cooperative, the binding of RNA is not.  It is not clear what the reason is for this 
difference.  Since most RNA molecules change conformation upon protein binding 
(Leulliot and Varani, 2001; Williamson, 2000), perhaps the RNA bound to 
carboxyltransferase assumes a conformation that does not induce cooperative binding.  
Thus, DNA binding may cause an induced fit in carboxyltransferase while RNA binding 
results in an induced fit of the RNA.   
Pharmaceutical Relevance 
The presence of the zinc finger domain and the finding that DNA binding inhibits 
enzymatic activity is very important for developing pharmaceutical agents specific for 
bacterial carboxyltransferase.  Acetyl-CoA carboxylase and, therefore, 
carboxyltransferase is found in humans as well as in bacteria.  Thus, antibiotics that target 
acetyl-CoA carboxylase will have to achieve species specificity in order to minimize 
toxicity.  Since the eukaryotic form of carboxyltransferase does not have a zinc domain, 
inhibitors binding to the zinc domain of the bacterial enzyme are likely to be species 
specific.  The findings in this report demonstrate that molecules that bind to the DNA 
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binding site will likely inhibit enzymatic activity since DNA binding and catalysis are 
reciprocally coupled. 
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CHAPTER 3 
INHIBITION OF THE CARBOXYLTRANSFERASE SUBUNIT OF ACETYL-COA 
CARBOXYLASE FROM ESCHERICHIA COLI AND STAPHYLOCOCCUS 
AUREUS BY TETRACYCLINES 
Introduction 
The first member of the tetracycline group of antibiotics was discovered in the 
late 1940s when chlortetracycline (Figure 3-1 and Table 3-1) was found to be produced 
by Streptomyces aureofaciens (Duggar, 1948).  The isolation of oxytetracycline and 
demeclocycline (Figure 3-1 and Table 3-1) soon followed along with tetracycline (Figure 
3-1 and Table 3-1) which was also produced by Streptomyces aureofaciens (Nelson, 
2001).   
Tetracycline could also be synthesized by catalytic hydrogenation of 
chlortetracycline (Nelson, 2001).  Tetracyclines exhibit a broad spectrum of activity 
against both gram-positive and gram-negative bacteria as well as chlamydiae, 
mycoplasmas, rickettsiae and protozoan parasites (Chopra and Roberts, 2001).  
Tetracyclines mode of action involves inhibiting protein synthesis by binding to the 30S 
subunit of the ribosome and preventing the binding of the incoming acylated tRNA 
(Chopra and Roberts, 2001).  In 1973, workers (Vanek et. al., 1973) described 
oxytetracycline mediated inhibition of acetyl-CoA carboxylase (and pyruvate 
dehydrogenase) in S. aureofaciens. Here we characterize the inhibition mechanism on the 
carboxyltransferase subunit of acetyl-CoA carboxylase from gram-positive and gram-
negative bacteria. 
Acetyl-CoA carboxylase (ACC) catalyzes the first committed and regulated step 
in fatty acid biosynthesis in bacteria via a two-step reaction (Scheme 1). 
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Figure 3-1. Stick Rendering of a Basic Tetracycline Molecule.  R groups at positions 1 – 
4 for several derivatives of tetracycline are detailed in Table 3-1. 
Table 3-1. Functional Groups for Tetracycline and Derivatives. Derivative names and 
functional groups at positions R1 – R4 are shown.  Species of origin for each derivative is 
listed; semisynthetic means the molecule is a result of synthetic modification of a 
naturally occurring precursor molecule. 
Derivative R1 R2 R3 R4 Origin 
      
Tetracycline H CH3 OH H Streptomyces rimosus/ aureofaciens 
Chlortetracycline Cl CH3 OH H Streptomyces aureofaciens 
Demeclocycline Cl OH H H Streptomyces aureofaciens 
Oxytetracycline H CH3 OH OH Streptomyces rimosus 
Minocycline N(CH3)2 H H H semisynthetic 
Doxycycline 
Anhydrotetracycline 
H 
H 
CH3 
CH3 
H 
C 
OH 
H 
semisynthetic 
Streptomyces rimosus/ aureofaciens 
      
      
 
 
Scheme 1 
OH
CONH2
N(CH3)2
O
OH
OHO
R1 R2 R3
H
R4
H
OH
(1)  Enzyme-biotin  +  MgATP  +  HCO3
-
Mg2+
Enzyme-biotin-CO2
-  +  MgADP  +  Pi
(2)  Enzyme-biotin-CO2
-  +  Acetyl CoA Malonyl CoA  +  Enzyme-biotin
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In gram-positive and gram-negative bacteria, ACC is composed of three separate 
proteins: biotin carboxylase, carboxyltransferase, and biotin carboxyl carrier protein 
(BCCP) (Cronan and Waldrop, 2002).  Biotin is covalently attached to BCCP and is 
designated Enzyme-biotin in Scheme 1.  Biotin carboxylase catalyzes the first-half 
reaction, which is an ATP-dependent carboxylation of biotin, to form carboxybiotin.  The 
second half-reaction is catalyzed by carboxyltransferase, which transfers the carboxyl 
group from carboxybiotin to acetyl-CoA to generate malonyl-CoA. 
Given the dramatic increase in antibiotic resistance of pathogenic bacteria there is 
a renewed interest in targeting fatty acid biosynthesis enzymes for antibiotic drug 
discovery (Campbell and Cronan, 2001, Zhang et al., 2006).  Since the metabolic role of 
acetyl-CoA carboxylase in bacteria is membrane biogenesis it is a prime target for 
antibiotics.  Inhibition of the carboxyltransferase subunit of acetyl-CoA carboxylase by 
tetracyclines not only provides new insight into the antibacterial mechanism but can also 
serve as a starting point for the design of new inhibitors of carboxyltransferase.    
Materials and Methods 
All the tetracycline derivatives were purchased from Sigma/Aldrich except 
anhydrotetracycline which was purchased from Cole-Parmer.  Heparin, coupling 
enzymes, NAD and DMSO were also from Sigma/Aldrich.  The 30-nt single-stranded 
sequence (5´-TGACCATGATTACGCCAAGCTATTTAGGTG-3´) used in the multiple 
inhibition studies, was obtained from MWG BioTech.  The bisubstrate analog (BiSA) 
was synthesized according to Levert and Waldrop (Levert and Waldrop, 2002). 
Purification and Enzymatic Assay of Carboxyltransferase 
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Carboxyltransferase from E. coli was purified from a strain of E. coli transformed 
with an overexpression plasmid containing a mini-operon with the genes for the α and β 
subunits of the enzyme (Blanchard and Waldrop, 1998).  Carboxyltransferase from S. 
aureus was purified as described by Bilder et al. (Bilder et al., 2006).  
Carboxyltransferase activity was measured in the reverse direction1 with a 
spectrophotometric assay in which the production of acetyl-CoA was coupled to the 
combined citrate synthase-malate dehydrogenase reaction requiring NAD+ reduction 
(Blanchard and Waldrop, 1998).  NADH formation was followed spectrophotometrically 
at 340 nm using a Uvikon 810 (Kontron Instruments) spectrophotometer interfaced to a 
PC equipped with a data acquisition program.  Since the crystal structure showed 
carboxyltransferase contained two active sites, the initial velocities were calculated per 
active site using a molecular weight of 68.5 kDa for each αβ dimer (i.e. active site).  
Measuring the activity of carboxyltransferase in the presence of tetracyclines with 
the above assay presented two problems that limited the concentration of tetracyclines 
that could be tested.  First, tetracyclines are sparingly soluble in water; therefore, all 
tetracyclines were dissolved in DMSO (dimethyl sulfoxide).  Thus, all velocities were 
measured with solutions containing 10% DMSO.  It is important to point out that 10% 
DMSO decreased the catalytic rate 32% , which does not agree with previously published 
reports (Santoro et al., 2006).  Second, NADH and tetracycline have an overlap in their 
absorbance spectra such that high concentrations of tetracycline masked the formation of 
NADH.  Therefore, a reference cuvette, containing all reagents in the sample cuvette 
except for carboxyltransferase, was used.  Both of these physical constraints placed an 
upper limit on the concentrations of tetracyclines that could be tested. Consistant with 
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previous reports (Vanek et. al., 1973), tetracyclines were not observed to inhibit the 
activity of either coupling enzyme. This was confirmed by measuring the reduction of 
NAD+ after adding a subsaturating concentration of acetyl-CoA rather than 
carboxyltransferase to a reaction mixture in the presence and absence of the tetracycline. 
Electrophoretic Mobility Shift Assays 
EMSAs were performed as described by Benson et al., (Benson et al., 2008).  
Briefly, the binding assays (total reaction volume of 10 µL) included 50 fmol of 300bp 
DNA, from the promoter region of the β gene of carboxyltransferase (Benson et al., 
2008), while carboxyltransferase was held at 0.8 µM.  The binding buffer was: 20 mM 
Tris-HCl (pH 8), 0.1 mM Na2EDTA, 0.075% BRIJ58, 50 mM NaCl, 5 mM MgCl2, 50 
µg/ml BSA, and 4% (v/v) glycerol.  Protein-nucleic acid complexes were equilibrated on 
ice for 0.5 h in the presence of oxytetracycline.  Samples were resolved on prerun 6.0% 
(w/v) native polyacrylamide gels (39:1 acrylamide:bisacrylamide) at room temperature in 
TBE buffer (45 mM Tris borate (pH 8.3), 1.25 mM Na2EDTA), and samples were loaded 
with the power on.  After 2.0 h of electrophoresis, the gel was dried and complexes were 
visualized by phosphorimaging. 
Data Analysis  
Competitive inhibition data were fitted to equation 1, using the programs of 
Cleland (Cleland, 1979).  In equation 1, v is the initial velocity, Vm is the maximal 
velocity, A is the substrate concentration, I is the concentration of inhibitor, Km is the 
Michaelis constant, and Ki is the inhibition constant.  Data for multiple inhibition were 
fitted to equation 2 where v is the initial velocity, I and J are the concentrations of the two 
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inhibitors, v0 is the velocity in the absence of inhibitors, Ki and Kj are the apparent 
dissociation constants for the two inhibitors, and β is a measure of the degree of 
interaction of the two inhibitors (Cleland 1990). 
v = Vm · A / Km (1 + I/Ki) + A         [1] 
  v = v0 / (1 + I/Ki + J/Kj + IJ/βKiKj)   [2] 
Results and Discussion 
Tetracyclines Inhibit Carboxyltransferase Activity 
Seven commercially available tetracyclines were tested for their ability to inhibit 
carboxyltransferase activity.  A titration of increasing amounts of each of the 
tetracyclines resulted in a corresponding decrease in the initial velocity of 
carboxyltransferase (Figure 3-2).  It was not possible to calculate an IC50 value for any of 
the derivatives in Figure 3-2 because the plateau region at high concentrations of the 
tetracyclines could not be determined due to overlap in absorbance spectra between 
NADH and the tetracyclines.  However, the estimated IC50 values for each of the 
derivatives ranges from about 100 µM to 800 µM.  Each of the tetracyclines inhibited 
carboxyltransferase from both E. coli and S. aureus.  Moreover, while it has been 
proposed that a magnesium-tetracycline complex is the species that binds to ribosomes 
(Chopra and Roberts, 2001) we found that magnesium did not increase the inhibitory 
effects of tetracycline (data not shown).  Tetracycline was used as a representative 
member of this class of antibiotics to determine the type of inhibition with respect to the 
substrates malonyl-CoA and biocytin.  Tetracycline exhibited competitive inhibition with 
respect to both malonyl-CoA and biocytin for E. coli (Figure 3-3 A and B) and S. aureus 
 106 
 
 
 
(Figure 3-3 C and D) carboxyltransferase. Fitting the data to equation 1 gave inhibition 
constants (Ki) of 194 ± 22 µM, with respect to malonyl-CoA, and 199 ± 15 µM, with 
respect to biocytin, for E. coli carboxyltransferase, while in the case of S. aureus 
carboxyltransferase, the Ki values for malonyl-CoA and biocytin were 110 ± 9 µM and 
245 ± 22 µM, respectively. 
 
 
Figure 3-2. A: Concentration Response Curve for Tetracyclines and E. coli 
Carboxyltransferase. B: Concentration response curve for tetracyclines and S. aureus 
carboxyltransferase. 
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Figure 3-3. Inhibition Patterns for Tetracycline Versus both Malonyl-CoA and Biocytin, 
respectively, with E. coli (A and B) and S. aureus (C and D) Carboxyltransferase.  When 
malonyl-CoA was the variable substrate, biocytin was held constant at 5.0 mM, and when 
biocytin was the variable substrate, malonyl-CoA was held constant at 0.1 mM.  The 
points are the reciprocal of the experimental velocities and the lines are derived from the 
best fit of the data to equation 1. 
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(Figure 3-3 continued) 
 
 
The competitive inhibition patterns indicate that the substrates and tetracycline 
compete for binding to the free enzyme.  Usually this means the substrates and inhibitor 
bind to the same site.  However, it can also mean that the inhibitor and substrate do not 
compete for the same binding site but that infinite levels of substrate simply prevent 
inhibitor binding.  Thus, to determine if tetracycline and substrate binding are mutually 
exclusive (or conversely can tetracycline and the substrates bind to the enzyme 
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simultaneously) multiple inhibition analyses were carried out using a bisubstrate analog 
(BiSA) inhibitor of carboxyltransferase, in which coenzyme A is covalently attached to 
carboxybiotin as an active site ligand (Levert and Waldrop, 2002). 
Multiple inhibition experiments are carried out by measuring the initial velocity at 
increasing concentrations of one inhibitor while the second inhibitor is held constant.  
The initial velocities are measured again at higher levels of the second inhibitor and then 
plotted as 1/velocity versus the concentration of the first inhibitor (sometimes referred to 
as a Yonetani-Theorell plot) (Yonetani and Theorell, 1964).  It is important to keep in 
mind that unlike the inhibition studies in Figure 3-2 where the substrate concentrations 
are extrapolated to infinity, the substrate concentrations in multiple inhibition 
experiments are held constant at subsaturating levels which allows both inhibitors to bind 
to the enzyme.  Double inhibition of carboxyltransferase by BiSA and different fixed 
levels of tetracycline yielded intersecting patterns (Figure 3-4A), which indicate that the 
two inhibitors can bind to the enzyme simultaneously and suggests the binding site for 
tetracycline and the active site of the enzyme are topologically distinct.  Fitting the data 
to equation 2 yielded a value of 0.3 for the β parameter which is an indication of the 
interaction of the two inhibitors.  Values of β greater than 1 indicate that the binding of 
the two inhibitors interfere with one another, while a value of 1 indicates no interaction 
between the inhibitors.  A β value less than 1 indicates synergism in the binding of the 
inhibitors.  Thus, the binding of tetracycline shows very weak synergism with the binding 
of BiSA and vice versa.   
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Figure 3-4. Double Inhibition Plots of Tetracycline Versus: DNA (A), Heparin (B), and 
BiSA (C) for E. coli Carboxyltransferase.  The points are the reciprocal of the 
experimental velocities and the lines are derived from the best fit of the data to equation 
2.  Malonyl-CoA was held constant at 0.1 mM, while biocytin was held constant at 5.0 
mM. 
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 (Figure 3-4 continued) 
 
Effect of Tetracycline on DNA Binding 
The crystal structures of carboxyltransferase from E. coli carboxyltransferase and 
S. aureus revealed that the β subunit contains a zinc finger domain on the amino terminus 
(Bilder et al., 2006).  Zinc fingers are commonly found in proteins that bind DNA and 
carboxyltransferase was recently found to bind DNA non-specifically (Benson et al., 
2008).  The DNA analog heparin also bound to carboxyltransferase and both DNA and 
heparin inhibited enzymatic activity (Benson et al., 2008).  Thus, given that the zinc 
domain is not found in the Streptomyces genera (Diacovich et al., 2004) which synthesize 
tetracyclines perhaps tetracycline inhibited carboxyltransferase by binding to the DNA 
binding site.  To investigate whether DNA and tetracycline share the same binding site on 
carboxyltransferase we utilized an electrophoretic mobility shift assay (EMSA) and 
multiple inhibition analyses.  As shown in the EMSA in Figure 3-5, increasing amounts 
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of oxytetracycline did not inhibit formation of the carboxyltransferase-DNA complex 
suggesting that tetracycline and DNA do not compete for the same binding site.  These 
results are consistent with multiple inhibition analyses with DNA and heparin.  Both 
DNA and heparin exhibited intersecting patterns with tetracycline (Figure 3-4 B and C) 
indicating that both tetracycline and DNA or heparin can bind to the enzyme 
simultaneously.  Moreover, the β values (1.08 and 0.95 for DNA-tetracycline and 
heparin-tetracycline, respectively) indicate there is no interaction between DNA or 
heparin and tetracycline.  
 
Figure 3-5. Oxytetracycline Effects on the DNA Binding Ability of Carboxyltransferase.  
Reactions in lanes 1 - 7 have 50.0 fmol of 300bp radio-labeled DNA carboxyltransferase 
β promoter DNA (Benson 2007), reactions in lanes 2 - 7 have 800.0 nM 
carboxyltransferase, oxytetracycline is titrated in the reactions from lanes 3 - 7 (from 35.0 
µM to 700.0 µM). 
While the multiple inhibition and EMSA studies indicate that tetracycline does 
not bind to either the active site or the DNA binding site it is not clear where tetracycline 
binds to carboxyltransferase.  What is known is that the binding of tetracycline to 
carboxyltransferase is prevented at saturating levels of either substrate, therefore, any 
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tetracycline binding site must be affected by substrate binding.  A possible binding site 
for tetracycline may be the interface between the αβ dimers (Figure 3-6).  Binding at the 
αβ dimer interface would allow access to the active site and the zinc domain and 
saturation with either substrate could induce a conformational change that prevents 
tetracycline binding.  Tetracycline binding would also disrupt communication between 
the two αβ dimers that comprise the active sites.  It has already been shown that the two 
active sites communicate at least with respect to DNA binding (Benson et al., 2008). 
 
Figure 3-6. Ribbon Drawing of Carboxyltransferase from S. aureus.  The α-chain is in 
purple and the β-chain is in gold.  The zinc atom is depicted as a blue sphere in the β-
chain. 
Does Tetracycline Bind Carboxyltransferase in Vivo?  
For many years, authors have stressed the similarities between tetracycline or 
polyketide biosynthesis and biosynthesis of fatty acids.  Similarities respective of both 
biosynthesis mechanisms and primary sequences of critical enzymes in both pathways 
have caused investigators to postulate that the enzymes evolved from a common origin 
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after early gene duplication (Revill et al., 1996); a brief overview of the most pertinent 
reactions in both pathways follows.   
In Streptomyces, fatty acid synthase catalyzes the formation of fatty acids (Revill 
et al., 1995).  Ketoacyl carrier protein synthase (FabH in initiation and FabB in 
elongation) catalyzes a decarboxylative reaction with acyl-ACP substrate and malonyl-
ACP.  The resulting 3-ketoacyl-ACP product is then modified via reduction, dehydration, 
and enoyl reduction, leading to an extended acyl-ACP product.  This product serves as 
the substrate for subsequent elongation by FabB.  The malonyl-ACP extender unit, acting 
as a substrate for FabB and FabH, is generated from malonyl-CoA by the action of 
malonyl-CoA:ACP transacylase (FabD).   
Similarly in polyketide biosynthesis, malonyl-CoA is used.  Specifically, nine 
molecules of malonyl-CoA and a series of oxytetracycline biosynthesis gene cluster 
products catalyze the formation of oxytetracycline, one of the earliest derivatives of 
tetracycline to be produced.  This reaction requires a minimal polyketide synthase, 
namely: ketosynthase, chain length factor, and an acyl-carrier protein, named OxyA, 
OxyB, OxyC (also called TcmM), respectively; and a malonyl-CoA:ACP transacylase, 
FabD (Florova et al., 2002; Hertweck et al., 2007; Zhang et al., 2006), borrowed from 
fatty acid synthesis.  In an iterative process, these enzymes, along with malonyl-CoA, 
generate the polyketide backbone of tetracycline.   
Tang and co-workers showed that OxyD, an amidotransferase homolog, 
incorporates an amide unit into the polyketide backbone.  The structure generated 
spontaneously cyclizes, via C11 – C16 regioselectivity, to produce a molecule Tang 
termed WJ85 (Pickens and Tang, 2009, Figure 3-7), which at this point resembles both 
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tetracycline and a polymerized moiety of malonyl-CoA.  Subsequent enzymatic reactions 
produce anhydrotetracycline, followed by oxytetracycline, and finally tetracycline. 
 
Figure 3-7. Stick Rendering of an Early Minor Product, Resembling Malonyl-CoA in the 
Tetracycline Synthesis Pathway (Pickens and Tang, 2009). 
Florova and colleagues noted that in Streptomyces, the acyl carrier proteins 
carrying malonyl-CoA, FabC (in fatty acid synthesis) and OxyC (in polyketide 
biosynthesis), are interchangeable.  However, it appears that only FabD covalently links 
malonyl-CoA to the carrier proteins FabC and OxyC.  Having similar affinities for both, 
FabD thus provides another tangible link between the two pathways (Revill et al., 1996).  
However, Florova also noted that the KCAT for the enzyme in fatty acid synthesis is nearly 
four times that of the comparable enzyme in polyketide biosynthesis reaction.  Thus, it is 
possible that, under normal conditions, malonyl-CoA is primarily utilized in fatty acid 
synthesis, but under conditions of nutrient stress, i.e., phosphate deprivation (Votruba and 
BÄ›hal,1984), malonyl-CoA is diverted to polyketide biosynthesis and tetracycline is 
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made.  Potentially, tetracycline acts here to tip the scale towards polyketide biosynthesis 
and away from fatty acid synthesis. 
 
 
 
 
 
 
  Figure 3-8. Two Possible Fates of Malonyl-CoA in Streptomyces 
Literature suggests that during the stationary phase when fewer fatty acids are 
needed, secondary metabolites increase, thus tetracycline biosynthesis increases.  
Interestingly, cultures of Streptomyces incubated for long periods show an increase in the 
production of tetracycline just prior to autolysis.  The addition of tetracycline to cultures 
during exponential growth phase abolishes tetracycline biosynthesis, while only partially 
reducing protein synthesis (Vanek et al., 1973).  Moreover, Vanek and coworkers 
observed inhibition of ACC by chlorotetracycline in Streptomyces; therefore tetracycline 
potentially contributes to the regulation of both pathways at lower concentrations, prior to 
bacteriostatic effects at higher concentrations. 
Interestingly, and perhaps counterintuitively, in vitro transcription assays using 
ribosomes isolated from tetracycline-producing organisms revealed increased sensitivity 
in organisms producing the antibiotic when compared to those incapable of its 
fatty acid biosynthesis                bacterial growth  
abundant nutrients 
 
malonyl-CoA 
           
limited nutrients  
polyketide (TET) biosynthesis      territory establishment 
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production.  This is likely due to the absence of protection/resistance mechanisms present 
in vivo (Mikulik et al.,1983).   
As the work discussed in this manuscript was conducted on carboxyltransferase 
from E. coli and S. aureus, tetracycline’s effects on carboxyltransferase from 
Streptomyces remain unknown.  If tetracycline were also to weakly inhibit 
carboxyltransferase from Streptomyces, one may wonder if this were part of a survival 
mechanism employed by the organism.  Conceivably, if tetracycline strongly inhibited 
carboxyltransferase, fatty acid synthesis would decrease too quickly upon the onset of 
tetracycline biosynthesis.  The potential for tetracycline to regulate fatty acid synthesis 
and polyketide biosynthesis in Streptomyces remains, however testing this theory should 
prove difficult without understanding the in vivo protection mechanisms involved in fatty 
acid synthesis, analogous to the in vitro transcription assays discussed.   
It is worth noting that, unlike in Streptomyces, the only known fate of malonyl-
CoA in E. coli is the synthesis of fatty acids (James and Cronan, 2004).  Perhaps in E. 
coli tetracycline does not serve as a switch to direct malonyl-CoA between fatty acid 
synthesis and polyketide biosynthesis; rather, it only inhibits fatty acid synthesis, aside 
from inhibiting translation.   
Structural analysis and comparison of the ribosome, carboxyltransferase, acetyl-
CoA, and tetracycline may be telling.  Analysis of the ribosome-tetracycline complex 
reveals extensive hydrogen bonding between tetracycline hydroxyls and the phosphate 
backbone of RNA at the A-site, in addition to hydrophobic interactions between the 
tetracycline rings and the RNA bases (Pioletti et al., 2001).  The ribosomal A-site and 
acetyl-CoA binding site on carboxyltransferase are both solvent exposed clefts.  
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Preliminary superpositions of tetracycline interacting with the substrate-occupied acetyl-
CoA binding site of carboxyltransferase suggest a possible fit whereby, acetyl-CoA 
presents phosphate oxygen atoms that interact with tetracycline in much the same way 
that RNA-presented phosphate oxygen atoms in the ribosomal A-site of the ribosome-
tetracycline complex.   
This observation is supported by our data, suggesting that both tetracycline and 
DNA (or presumably RNA) can bind to the enzyme simultaneously while not occupying 
the same site, and tetracycline and the substrates can bind to the enzyme simultaneously.  
Another possibility is that the tetracycline disturbs the placement of the aliphatic tail of 
acetyl-CoA.  Although this disruption could allow acetyl-CoA binding via the nucleotide 
binding portion of the molecule, the active part of acetyl-CoA (namely, the pantetheine 
moiety sitting in a hydrophobic cleft) at the interface between the alpha and beta subunits 
of carboxyltransferase, could be filled by tetracycline.   
Additionally, just as there are hydrophobic interactions between tetracycline and 
the RNA bases of the bacterial ribosome, there may be equivalent interactions between 
the tetracycline and the hydrophobic residues in the active site of carboxyltransferase.  
Lastly, the reduced affinity of tetracycline for carboxyltransferase compared to the 
ribosome may be supported by the loss of hydrophobic interactions and fewer, less-
specific hydrogen bonding interactions.  In the context of these potential mechanisms of 
inhibition, it is important to point out that the mechanism of action for tetracyclines has 
been questioned, and the actual mechanism of action is still unknown (Schnappinger and 
Hillen, 1996).  
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Pharmaceutical Relevance 
The fact that tetracyclines inhibit carboxyltransferase is not only helpful for 
understanding the mechanism of action of this class of antibiotics but it also provides a 
starting point for developing more potent inhibitors with pharmacological properties.  
There is precedent for carboxyltransferase as a target for antibiotics.  For instance, the 
antibiotic moiramide B was found to inhibit carboxyltransferase (Freiberg et al., 2004); 
however, moiramide B is not used clinically presumably due to toxicity effects.  Thus, 
there is a need to find other more specific potent inhibitors of carboxyltransferase that 
could serve as antibiotics.  The tetracyclines could serve as a lead compounds in the 
design of more effective pharmaceutical agents targeting the carboxyltransferase 
component of acetyl-CoA carboxylase.         
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CHAPTER 4 
CONCLUSION 
 
Fatty acids are the most energetically expensive modules to biosynthesize; thus, 
the regulation of fatty-acid production is tightly controlled via multiple mechanisms to 
match the growth rate of cells (Zhang and Rock, 2009). And though it is unlikely that a 
single paradigm exists for regulation of fatty-acid synthesis in prokaryotes, this work 
reveals an interesting mechanism enabling Escherichia coli to maintain stoichiometric 
amounts of both subunits of carboxyltransferase despite the separate chromosomal 
locations of the two genes.  
Much of this work was inspired by the three-dimensional structural information of 
E. coli and Staphylococcus aureus carboxyltransferase revealing a zinc finger, or 
presumptive DNA-binding domain (Bilder et al., 2006). After I confirmed DNA binding, 
much to my surprise, I discovered that DNA and heparin inhibit the reaction catalyzed by 
carboxyltransferase, as does a class of antibiotics, tetracycline. The results from this 
tetracycline study led me to propose a regulatory role for tetracycline in fatty-acid 
biosynthesis in the tetracycline-producing organisms. Furthermore, I suggest that 
carboxyltransferase is an alternate, albeit minor, target in the mechanism of action for the 
antibiotic tetracycline. The final aspect of my work revealed RNA was both an inhibitor 
and a ligand of carboxyltransferase. 
Though DNA-binding studies revealed low-affinity, cooperative and nonspecific 
interactions, a RNA-binding study revealed non-cooperative binding with a 7-fold higher 
affinity to the transcripts of AccA/D. Just as this work built upon the carboxyltransferase 
structural information and was made possible by the overexpression, purification and 
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real-time spectrophotometric assay, it provided the lead-in for further characterization of 
RNA binding and the discovery of the biological target.  
Subsequent Studies 
Upon completion of my work, RNA binding and the carboxyltransferase zinc 
finger became the focus of future investigations. Meades, et. al. concluded that the 
enzyme interacts with RNA in situ via the zinc finger and that this motif is necessary for 
catalysis (Meades, et. al., 2010). He demonstrated that in vitro translation of AccA/D is 
inhibited upon the addition of carboxyltransferase, and this inhibition is reversed with 
acetyl-CoA. These results were consistent with DNA-binding studies that showed a loss 
of DNA binding by the enzyme in the presence of the substrates. Likewise, and again 
consistent with DNA-binding studies, mRNA encoding either subunit of 
carboxyltransferase inhibits catalysis. Consequently, Meades, et. al. proposed these 
seemingly independent occurrences are actually part of a coordinated negative feedback 
mechanism of control for acetyl-CoA carboxylase in E. coli that hinges on concentrations 
of acetyl-CoA (Figure 4-1). 
The model demonstrates that under conditions of limited nutrient growth and low 
intracellular acetyl-CoA the enzyme binds mRNA from both subunits, attenuating 
translation and catalysis (Meades et. al., 2010). Conversely, in the presence of high 
nutrients the intracellular concentration of acetyl-CoA rises and mRNA is displaced from 
the enzyme, providing for rapid translation of previously synthesized transcripts.  Most 
significantly, this translational regulation model illustrates the mechanism whereby E. 
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coli produces stoichiometric amounts of both subunits of carboxyltransferase despite the 
fact that these genes are within separate operons. 
 
 
Figure 4-1. Negative Feedback Model for Autoregulation of Translation and Catalysis is 
Centered on the Intracellular Concentration of Acetyl-CoA. The left half of the figure 
represents limited nutrient growth conditions, and low intracellular acetyl-CoA 
concentration, whereas the right half of the figure represents high nutrient and 
intracellular acetyl-CoA levels. 
 
 
Given the high affinity carboxyltransferase demonstrated toward its own 
transcripts and the fact that the enzyme was noted to have virtually no affinity for another 
mRNA (encoding an EF-Ts), an obvious question arose: What recognizable features in 
the AccA/D transcripts permit tight binding? The answer came after extrapolating the 
chemical symmetry in the carboxyltransferase-catalyzed reaction to the structural 
symmetry between the subunits (Waldrop, 2011). During catalysis, enolate-like anions 
form on acetyl-CoA and biotin. Both subunits of carboxyltransferase have oxyanion holes 
(Bilder et al., 2006) that stabilize these enolate species. Likewise, within both genes, 
63 
 
 
Figure 2.9  Proposed mechanism for autoregulation of CT enzymatic activity and mRNA 
translation.  The RNA-binding and catalytic functions of CT are sensitive to the metabolic state 
of the cell.  During stationary phas  when de n vo fatty acid synthesis is unneeded, glucose and 
thus acetyl-CoA levels are low, allowing CT to bind the mRNA for its subunits, attenuating 
expression of the enzyme as well as enzymatic activity on remaining acetyl-CoA stores. During 
log phase growth membrane biogenesis is needed.   Glucose is abundant, increasing the 
availability of acetyl-CoA for fatty acid synthesis.  Acetyl-CoA binds to CT permitting 
translation of the mRNA for the ! and " subunits. This "dimmer switch" model gives the cell a 
means of rapid response to changes in cellular metabolic state. 
 
is not found in eukaryotic carboxyltransferase because the ! and " subunits are fused to one 
another as well as to the BC and BCCP components to form one polypeptide chain and because 
the zinc domain is absent (Bai et al, 1986).  The one exception to the multidomain homomeric 
ACCase found in eukaryotes is the heteromeric ACCase found in plastids.  The chloroplast 
ACCase of all plants except for the grasses (Graminae) consists of the same four subunits as E. 
coli ACCase, but their genetic origins are different (Nikolau et al, 2003).  The BC, BCCP, and 
CT ! peptides originate from nuclear-encoded genes and are shuttled to the chloroplast (Bao et 
al, 1997; Sun et al, 1997; Ke et al, 2000).  The CT " protein, however, is expressed from a 
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similar regions exist that code for the oxyanion holes, and it is these “symmetrical boxes” 
along with coding regions upstream of these boxes that are described as necessary for 
high-affinity mRNA binding by carboxyltransferase (Meades et. al., 2010). 
Future Directions 
The overall goal of this research is to fully understand the mechanisms of control 
for acetyl-CoA carboxylase in E. coli, yet questions warranting further investigation 
remain. Over the next few paragraphs, several analytical techniques that may provide 
answers to these questions are discussed. However, the utility of these experiments lies in 
their capacity to provide structural information for both transcripts and to trap 
carboxyltransferase bound to nucleic-acid substrate(s). 
The first unanswered questions are: Does carboxyltransferase bind the AccA/D 
transcripts in vivo? If so, under what environmental conditions? And, does the enzyme 
bind additional nucleic-acid ligands? Though it has been shown, via an in vitro 
transcription/ translation assay, that carboxyltransferase does inhibit translation of 
AccA/D, and not translation of a 32kDa EF-Ts (Meades et. al., 2010), it has not been 
shown that the enzyme binds AccA/D in vivo. Thus, a gentle purification of a 
carboxyltransferase:RNA complex, using the incorporation of high-affinity epitope tags 
engineered into AccA/ AccD, may help to elucidate the in vivo nucleic-acid binding 
target(s). The co-purified complex can be UV crosslinked and the bound mRNA 
sequenced  (Puig et. al., 2001).  
Another curious question is: If carboxyltransferase were exposed to a large pool 
of random sequence RNA molecules, what sequence(s) would yield the tightest binding? 
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Systematic Evolution of Ligands by EXponential enrichment, or SELEX, may help 
answer this question. Though this experiment is an in vitro selection technique used to 
screen for nucleic-acid ligands (Klug and Famulok, 1994), a high-affinity RNA could be 
sequenced and compared against the genome, thus producing likely in vivo substrates. It’s 
possible that a high-affinity RNA molecule(s) amplified by SELEX would be similar in 
sequence to AccA and/ or AccD, thus reinforcing the theory that carboxyltransferase binds 
the transcripts that encode both subunits in vivo. 
Obtaining co-crystal structures of carboxyltransferase and the transcript for either 
subunit appears unlikely given the large size of the transcripts; therefore, other means of 
obtaining three-dimensional structural information is necessary. Insights regarding the 
interaction of the zinc-finger domain and mRNA may be gleaned with hydrogen-
exchange mass spectrometry, as this technique may help map the nucleic-acid-binding 
site(s) on the enzyme (Hoofnagle, et al., 2003). This experiment may reveal whether one 
mRNA spans both zinc-fingers or if one molecule of enzyme binds a single or multiple 
(separate) transcript(s). 
To further support the theory that the symmetry boxes within the AccA/D 
transcripts are the structurally recognizable features that drive high-affinity binding by 
carboxyltransferase, a better characterization of these regions is necessary. In doing so, 
comparing the secondary structures of these symmetry boxes and their upstream regions 
remains essential. Two experiments that may help elucidate secondary structure 
characteristics in these regions are: in-line probing (Gopinath, 2009) and selective 2'-
hydroxyl acylation analyzed by primer extension, or SHAPE analysis (Merino et al., 
2005). Hopefully, results from these experiments may allow for the design of RNA 
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oligomers, identical to the portions of the transcripts thought to interact with 
carboxyltransferase, for co-crystallographic studies. 
Follow-up investigations shedding light on the biological significance of 
tetracycline-inhibiting carboxyltransferase remain relevant. If obtaining novel derivatives 
of tetracycline is possible, inhibition studies may uncover better enzyme inhibitors. 
Furthermore, if a tight-binding inhibitor were discovered, solving a co-crystal structure 
may allow for visualization of the atomic contacts. Taken together, these results could 
guide the design of subsequent-generation, high-potent inhibitors of the enzyme, while a 
better understanding of the mechanisms of inherent or acquired bacterial resistance to 
tetracycline may help us design lasting antibiotics in this class. 
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APPENDIX B 
ABBREVIATIONS 
 
ACC   acetyl-CoA carboxylase 
Ala   alanine 
AOPP    aryloxyphenoxypropionate 
Arg   arginine 
Asp   aspartic acid 
BCCP   biotin carboxyl carrier protein  
BirA    biotin holoenzyme synthetase 
BiSA    bisubstrate analog 
C2′   carbon within ureido ring, see Figure 1-1. 
C-terminal  carboxyl-terminal 
CHD   cyclohexanediones 
EF-Ts   elongation factor thermo stable 
E. coli   Escherichia coli  
EMSA   electrophoretic mobility shift assay 
FAS-I    type I fatty acid synthase  
FAS-II   soluble enzymes in prokaryotes and plant chloroplasts 
IHF   integration host factor  
I, Ile   isoleucine  
Lys   lysine 
Met   methionine 
N1′   nitrogen within urido ring, see Figure 1-1. 
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N3′    nitrogen within urido ring, see Figure 1-1. 
N-terminal   amino-terminal 
NMR   nuclear magnetic resonance 
Pi   Inorganic phosphate 
T, Thr   threonine 
Tyr   tyrosine 
Val   valine 
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APPENDIX C  
ANALYTICAL TECHNIQUES APPLIED TO NUCLEIC-ACID BINDING PROTEINS 
 
It became clear at the beginning of this work that studying DNA-protein 
interactions via an agrose gel would be insufficient, so we pursued a more acceptable 
method.  As electrophoretic mobility shift assays, or EMSAs, were essential to this thesis, 
yet not previously performed in our laboratory, a literature review concerning the 
detection and study of DNA-binding proteins was necessary and proved insightful. 
Several methods have been developed and enhanced to the point of current gel shift 
assays. Initially, two groups (Coombs and Pearson, 1978; Riggs et al., 1970) developed 
the filter assay to retain DNA-protein complexes on a nitrocellulose filter. Subsequently, 
an abortive initiation assay was developed to visualize an RNA polymerase reaction in 
1978 using paper chromatography (McClure et al., 1978). Finally, in 1979, one group 
(Chelm and Geiduschek, 1979), in an agrose gel electrophoresis assay, studied the very 
stable ternary transcription complexes. These complexes were composed of RNA 
polymerase, DNA and radioactively labeled nascent RNAs. This method provided 
information on polymerase binding and on promoter mapping by identification of DNA-
restriction fragments. These DNA-restriction fragments generated measurable ternary 
complexes. 
Though several groups prior to 1981 had reported methods for studying 
protein:DNA complexes, it was Garner and Revzin (Garner and Revzin, 1981) who first 
described a new protein:DNA gel shift, or EMSA, as “a new gel electrophoresis 
technique for more quantitative studies of specific protein:DNA interactions.” They 
explained that this method could separate unbound DNA fragments from complexes by 
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electrophoresis in polyacrylamide gels. The amount of unbound DNA is then determined 
by densitometry of the gel. They proclaimed that this fast and easy method used small 
amounts of reagents. 
Around the same time, Fried and Crothers also described the utility of EMSA. In 
an article also published in Nucleic Acids Research only months after Garner and Revzin 
published their findings, Fried and Crothers (Fried and Crothers, 1981), who have since 
been credited with developing this technique, explained that “the protein is mixed with 
one or more DNA fragments, and protein:DNA complexes are resolved as discrete bands 
by polyacrylamide gel electrophoresis, with mobilities decreasing as a function of the 
number of proteins bound to a given DNA fragment.” They suggested that, under 
minimal ionic strength conditions, the gel matrix itself stabilizes the complex against 
dissociation. Potential factors for strengthening the complex include: volume exclusion, 
direct interaction with gel matrices, and the reduction of water activity by the gel. While 
one may wonder if this technique could cause artificially high affinities for protein:DNA 
complexes, the group has reported that the parameters appear no different in the gel than 
in an ordinary buffer (Fried and Bromberg, 1997). Fried and Crothers added that the 
benefit of the EMSA technique was the measuring, via microdensitometry, of stained gels 
and gel autoradiograms for the quantification of the protein and DNA present in each 
complex (Fried and Crothers, 1981). Furthermore, the technique permitted determination 
of the stoichiometric ratio of protein specifically bound to DNA, and it facilitated precise 
measurement of the relative binding affinities of a given protein for two different nucleic 
acids. Next, dissociation kinetics is readily obtainable for long-lasting protein:DNA 
complexes. Most importantly, in addition to use in quantitative binding studies, this 
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technique should simplify identification of proteins that bind specifically to a given DNA 
sequence or of restriction fragments containing sequences recognized by a particular 
protein. 
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